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CHAPTER 1
STUDY OVERVIEW
Chronic pain and substance abuse/dependence both cause substantial individual
suffering and societal costs. Brooner (2008) states that “substance use disorders and
chronic pain produce an impressive and strikingly similar range and number of negative
effects on humans and society, and cause notable concerns and dilemmas…across the
entire health care treatment system” (p. 485). Although effective interventions for each
of these conditions have been developed, chronic pain and substance misuse are often
co-morbid. Unfortunately, the field currently lacks guidelines for identifying chronic pain
patients who are at high risk for prescription misuse and/or substance abuse, and there
is a need for research to help clinicians understand who is most likely to misuse their
prescriptions or other substances while receiving treatment for chronic pain (Turk,
Swanson, & Gatchel, 2008). Identifying patients most at risk for developing prescription
or substance use problems can lead to better targeting of substance abuse prevention
and treatment among people with chronic pain.

However, research is limited on

substance abuse, particularly prescription opioid misuse, within chronic pain
populations.
Notably, similar factors, such as trauma history and low social support, have
been implicated in the development and maintenance of both chronic pain and
substance abuse. The shared risk factors for the development of chronic pain and
substance abuse highlight the need for further research into the relationship of chronic
pain and substance abuse. The limited predictive factors applied to prescription opioid
abuse in chronic pain patients is surprising given the breadth of personal, cognitive, and
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emotional factors explored in the separate literatures on chronic pain and substance
abuse. Prior research has examined, without conclusive results, the predictive factors of
previous substance abuse, age, gender, and prior history of psychiatric diagnoses
(Michna et al., 2004).
Physicians treating chronic pain patients are in the difficult position of identifying
any signs of prescription drug abuse and preventing abuse of other substances, yet
they lack evidence-based guidelines to inform their decisions. Daily, physicians who
treat chronic pain patients are forced to make decisions about whether medication is
needed, whether the medication is effective, and whether there are any harmful effects
of use. There are currently few factors guiding physicians’ decisions as to whether an
individual patient may need additional regulation of pain medications because of risks.
One study showed that people who are regularly prescribed opioids for the treatment of
pain had increased rates of opioid and other substance abuse problems (Edlund,
Sullivan, Steffick, Harris, & Wells 2007), and did not have improved pain relief, quality of
life, or functional ability as compared to other pain patients not receiving medication
(Eriksen et al., 2006). These findings suggest that there are serious risks associated
with chronic prescription opioid use, and further research is needed.
Research on prescription misuse and substance use in chronic pain patients has
been limited in scope, likely due in part to researchers’ difficulties in defining
prescription misuse and inaccuracy in self-report. As many of the previous research
studies have been conducted using medical record review or conducted by individuals
closely tied to the patients’ treatment, reporting of prescription misuse and substance
use has likely been compromised. In clinical settings, gathering accurate information
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about personal history, prescription misuse, and substance abuse can be critical to
providing effective care. In research settings, gathering accurate information from
participants is critical to the fidelity of a study and the usefulness of interpretations.
Paper-and-pencil methods and clinician interviews—of varying skill and effectiveness—
are the most common methods of assessing this information, but the method used
appears to influence outcomes. For example, Gerbert et al. (1999) found that primary
care patients who completed a computerized form reported significantly more drug and
alcohol risk behaviors than those in a standard interview condition. The method by
which information is gathered from participants is known to significantly change the
outcome of studies. Literature specific to methods by which information about
stigmatized behaviors is gathered is still in its developmental phase, but much of the
work has focused on the use of computerized programs for eliciting sensitive
information (e.g., Newman et al., 2002) which may not be feasible to implement in direct
patient care. Doctor-patient interactions are the most likely time to collect information
about the risky behaviors of chronic pain patients in ongoing care, and these
interactions are nearly always face-to-face. There is a need to develop and test
methods to assess substance abuse and other stigmatized behaviors that can be easily
employed in clinical settings.
In this dissertation project, two major areas that have been inadequately studied
within the chronic pain literature were examined. First, although research has identified
several demographic and social factors that are implicated in the development and
maintenance of both chronic pain and substance abuse, little research has been done
on emotional risk factors, including a history of traumatic experiences and how one
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regulates one’s emotions. Although many people have hypothesized that emotional
factors contribute to both chronic pain and substance misuse, this needs to be tested in
patients who are co-morbid for both. The second area that was studied is the method by
which sensitive information, such as prescription misuse, substance abuse, and trauma
history, is gathered. There is a need to experimentally test clinically feasible methods of
enhancing patients’ reports of such stigmatized behaviors, and interviews using
enhanced communication techniques may accomplish this goal.
Overall, this study had several aims of substantial theoretical and practical
importance to the fields of medicine and psychology. The first goal was to determine
which demographic, pain-related, cognitive/social, and stress/emotional factors predict
the abuse of prescription or other substances among patients in treatment for chronic
pain. The second goal was to test whether knowledge of factors related to stress and
emotion regulation (low emotional awareness and expression, high experience and
impact of lifetime trauma) predict prescription and substance misuse beyond more
routinely assessed and established factors. The third goal was to compare different
methods of eliciting disclosure of stigmatized information (misuse of prescription
medication, use of alcohol/drugs, and experience of stressful events or traumas), and
test whether an innovative, clinically sensitive interview protocol will enhance disclosure
beyond a traditional interview and a questionnaire.
To address these aims, patients with chronic pain who were receiving opioid
treatment through a local pain management clinic were recruited. Participants
completed most of the predictor measures (i.e., demographic, pain, cognitive/social, and
emotional measures) in paper-and-pencil format, but were randomized to provide
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information about drug use and trauma history in one of three formats: a written (non
face-to-face) paper-and-pencil questionnaire, standard face-to-face clinical interview, or
an enhanced interview, in which the interviewer followed a scripted method for
encouraging further disclosure (e.g., normalizing the occurrence of prescription
misuse/trauma, discussing concerns of confidentiality in detail, etc.).
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CHAPTER 2
LITERATURE REVIEW
Chronic pain is defined as “pain that extends beyond the period of tissue healing
or with low levels of identified pathology that are insufficient to explain the presence
and/or extent of pain” (Jacobsen & Mariano, 2001). Chronic pain can be initiated by a
range of triggers (e.g., disease, injury), but it is maintained or aggravated by a variety of
additional psychological, behavioral, and environmental factors such as coping, stress,
decreased activity, and legal disability status (Visser, 2006). Chronic pain impacts the
lives of over 75 million people in the United States. It has a major impact upon our
health care industry, as chronic pain patients need increasing care as they try to
manage this debilitating condition (Becker, Fiellin, & Desai, 1997). Chronic pain is a
leading cause of disability and interference with job performance. There are limited
treatment options used for chronic pain patients. Traditional treatments for chronic pain
include the use of analgesic medications, but chronic pain is rarely fully controlled by
analgesics (Eriksen, Sjogren, Bruera, Ekholm, & Rasmussen, 2006). A statement in the
Research Reports Series: Prescription Drugs: Abuse and Addiction highlights the
common dilemma of treatment providers in the field of chronic pain: “How to adequately
relieve a patient’s suffering, while avoiding the potential for that patient to become
addicted to the pain medication. (pg. 7)”
Given the evidence that chronic pain is rarely controlled fully by analgesic
medications, we also know that patients may use other substances that are not
prescribed to try to manage pain on their own (Brennan, Schutte, & Moos, 2005).
Individuals with chronic pain have increased rates of substance abuse and psychiatric
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disorders (Twillman, 2007; Weisberg & Boatwright, 2007). The elevated rates of
substance abuse within chronic pain populations provides further support for the need
to develop better predictive models for abuse potential within chronic pain patients.
Like chronic pain, substance abuse and dependence also have a profound
impact on the lives of many people. Substance abuse and dependence are related to
significant work and relationship disability, are comorbid with other psychiatric illnesses,
are associated with lower quality of life, and are linked to serious health complications
(Hser, Hoffman, Grella, & Anglin, 2001; Maddux & Desmond, 1992; Marmorstein,
Iacono, & Malone, 2010; Research Society on Alcoholism, 2011). Much of the concern
about the potential abuse of prescription opioids has been spurred by concerns over the
non-medical use of prescription opioids, such as youth who have not been prescribed
the medication, the street sales of prescription drugs, and so on. The non-medical use
of prescription opioids has led to mounting concerns about preventing diversion of
prescriptions and identifying individuals most at risk of abusing those prescriptions.
Non-Medical Use/Abuse of Prescription Opioids
Becker, Sullivan, Tetrault, Desai, and Fiellin (2008) found that non-medical use of
prescription opioids was 4.5% and increasing, based on data from the 2002-2004
National Survey on Drug Use and Health. Within this 4.5%, some individuals were
misusing prescriptions provided for medically-valid reasons, and some individuals were
using the opioids without any medical need. Blanco et al. (2007) found similar results
using data from the National Longitudinal Alcohol Epidemiologic Survey and National
Epidemiologic Survey on Alcohol and Related Conditions. Blanco et al. compared data
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from 1991 and 2001 and found that non-medical use of prescription opioids had
increased 53% over that time period.
The fear of the significant impact that abuse of drugs has on a community,
coupled with the increasing use of non-prescription opioids, has raised concern within
the medical community about the appropriateness of prescribing these medications to
patients with chronic pain (Erikson, 2008). Despite this recent interest in the nonmedical use of prescription opioids, the long-term medical use of opioids and other
substances in a chronic pain population has not received as much research attention,
which is likely due, in part, to the complicated nature of defining substance misuse in
the population. The difficulty in defining prescription opioid misuse in chronic pain
populations is clearly illustrated in the varying estimates of the rates of misuse across
studies as noted below.
Prevalence of Opioid Misuse in Chronic Pain Populations
There is inconsistent evidence of prescription drug abuse within the chronic pain
population. Some studies report little to no abuse of prescription opioids (Cowan,
Wilson-Barnett, Griffiths, & Allen, 2003; Dellemijn, 2001); however, other studies cite an
increasing concern over misuse of prescriptions (Becker et al., 2008; Chabal, Erjavec,
Jacobsen, Mariano, & Chaney, 1997). Hoffmann, Olofsson, Salen, and Wickstrom
(1995) found that 23.4% of patients attending a chronic pain treatment center in
Sweden met criteria for abuse and/or dependence of alcohol, opioids, or sedatives. In a
review of the literature, Hojsted and Sjogren (2006) found that rates of prescription
opioid misuse in chronic pain populations ranged from 0 to 50%, depending on the
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definition of prescription abuse or misuse that was used and the method by which the
information was collected.
The difficulty in developing a clear definition of prescription abuse has been
complicated by an ethical debate about the utility and risk of pain medications in chronic
pain. There are likely few problems resulting from short-term use of opioid prescriptions;
however, as mentioned above, many patients with chronic pain are prescribed a longterm course of such medication. Daily use of prescription opioids leads to physiological
changes such as a need for increased dosage (tolerance) and withdrawal symptoms.
Sees and Clark (1993) suggested that a person who is prescribed opioids for pain could
potentially meet for DSM-IIIR criteria of dependence without truly being dependent in a
clinical sense. Additionally, Weissman and Haddox (1989) coined the term “pseudoaddiction” referring to time-limited and reversible abuse symptoms that are suggestive
of under-treated pain, rather than actual abuse or dependence. Another argument that
was proposed to encourage the liberal treatment of chronic pain patients with opioid
medications is the model of pain as an antagonist (a “block”) to the addictive properties
of opioids (Kanner & Foley, 1981; Portenoy & Foley, 1986). Debates as to the
meaningfulness of an abuse or dependence definition for prescription opioids have left
some researchers and clinicians skeptical that abuse of prescription opioids in a chronic
pain population even exists. Such skepticism could lead physicians and researchers to
ignore serious warning signs of addictive behaviors.
Alternatively, those on the opposite side of the debate over the meaningfulness
of abuse and dependence on prescription opioids have attempted to demonstrate that
all prescription opioids are dangerous. This belief could lead to under-treatment of
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patients with chronic pain, thus leading to further suffering. This side of the argument
has led to theoretical debates as to whether patients who present warning signs should
be prescribed any opiate pain medication. For example, Cohen, Jasser, Herron, and
Margolis (2002) published their own ethical dilemma as to whether a chronic pain
patient with previous history of abuse of any substance should be prescribed pain
medication at all.
Despite the polarization of this debate within the literature, it appears that the
need to relieve chronic pain patients of some suffering must be balanced with
consideration as to whether opioid prescriptions warrant increased regulation for clients
who present with risk factors for abuse. As stated by Erikson (2008), we need to
consider the substantial impact of drug dependence which affects nearly 100 million
people as opposed to the roughly 50 million with pain and also consider the cost to
society of substance abuse which has been estimated at nearly 4 times the cost of
“under-medicated pain (p. 1).” There are many theoretical publications on this debate,
but it is essential to consider the working definition of prescription misuse and also the
existing research studies that have begun to attempt to clarify the prevalence of
substance abuse and the risks associated with development of substance abuse in a
chronic pain population.
Defining Prescription Misuse
It is evident that there are many risk factors that remain to be explored to help in
identifying chronic pain patients most at risk for prescription misuse and substance
abuse. The ability to accurately identify misuse and appropriately assess it in both
clinical and research settings continues to place limits on the utility of our findings.

11
Finding the most effective methods for eliciting accurate information from participants
with chronic pain patients is a necessary step towards better identification of risk
factors.
There is inherent complication in identifying whether an individual is misusing a
prescription opioid, because as described previously, many of the problematic
symptoms of drug use, such as needing higher doses to get the same effect or
withdrawal symptoms will likely arise even with appropriate use of pain medications. To
address these complications, multiple scales have been developed to operationalize
opioid prescription misuse and aid physicians in making the judgment as to whether
their patients are misusing medications. Examination of a few of these scales provides a
better picture of the conceptualization of prescription drug misuse that has been
established thus far.
One such measure is the Pain Medication Questionnaire (PMQ) developed by
Adams et al. (2004). The PMQ is a list of aberrant, prescription drug related behaviors
and was developed based upon previous clinical research and feedback from clinical
personnel. The PMQ lists behaviors such as “I believe I would be better with a higher
dosage of my pain medication” or “At times I drink alcohol to control my pain” and
patients rate these items on a visual analogue scale. All of the items from this
questionnaire are based on current risk factors such as use of other substances,
personal concerns about their medication use, or need for increasing medication.
Another measure is the Prescription Drug Use Questionnaire (PDUQ), which explores
factors such as severity of pain, relationship with their treating physician, and current
prescription misuse variables (Compton, Darakjian, & Miotto, 1998). The PDUQ differs
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from the PMQ because of its explicit focus on pain and prescription factors rather than
assumed risk factors of family substance abuse history and other substance use. A third
established measure is the Screening for Addiction in Patients with Chronic pain and
“Problematic” Substance Use (SOAPP; Butler et al., 2004; Butler, Fernandez, Benoit,
Budman, & Jamison, 2008; Compton, Darakjian, & Miotto, 1998). The SOAPP was
established by an expert panel which identified and rated assumed risk factors for
prescription opioid abuse in a pain population. This scale includes questions regarding
history of substance abuse and legal problems. In summary, the primary scales used
currently to assess prescription opioid abuse in a chronic pain population focus either
on current substance misuse behaviors or past history of any substance abuse to make
predictions as to whether an individual patient is at risk. These established tools to
predict and detect misuse of prescription opioids are limited in scope, focusing only on
the narrow range of “risky” behaviors identified so far (e.g., illegal actions, misuse of
other substances, and/or past history of substance abuse).
Spurred by the lack of definition regarding misuse of prescription opioids, the
American Pain Society (APS), the American Society of Addiction Medicine (ASAM), and
the American Academy of Pain (AAP) developed a unified definition of misuse
(American Pain Society, 2001). As the American Pain Society reported, prior to this
definition, each medical specialty had developed its own criteria for diagnosing
prescription misuse. The definition provided by APS, ASAM and AAP is as follows: “a
primary,

chronic,

neurobiological

disease,

with

genetic,

psychosocial,

and

environmental factors influencing its development and manifestations.” Unfortunately,
this definition does not detail the thoughts, behaviors, and actions that should give
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practitioners warning about an at-risk or abusing patient. Ballantyne and LaForge
(2007), in a review of the literature, stated that the continued lack of a clear definition of
prescription opioid misuse has caused substantial interference in the identification and
treatment of chronic pain patients with an opioid addiction. Despite the efforts of APS,
ASAM, and AAP, it appears that we are still lacking an operational, working definition
from which to design our research questions and inform our treatment of chronic pain
patients. As described above, our definition of prescription misuse has been developed
in part by the working definitions used for research studies, and those studies will now
be reviewed.
Review of Prescription Opioid Misuse Research
The majority of the research on prescription opioid abuse in a chronic pain
population stems from large national studies such as the National Survey on Drug Use
and Health (Becker et al., 2008; Blanco et al., 2007; Compton & Volkow, 2006; Dowling,
Store, & Chilcoat., 2006; Edlund et al., 2007; Eriksen et al., 2006; McCabe, Teter, Boyd,
Knight, & Wechsler, 2005). One such study was conducted by Edlund et al. (2007), who
analyzed surveys of nearly 9,300 people to compare substance use problems between
individuals who have been regularly prescribed opioids and those who have not. The
study showed that people who are regularly prescribed opioids for the treatment of pain
had increased rates of opioid and other substance abuse problems compared to those
who were not prescribed opioids regularly. The authors reported that the increased
misuse of opioids and non-opioid substances in individuals prescribed opioids for pain
were likely due in part to increased rates of anxiety and depressive disorders for
individuals receiving prescription opioids.
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Another epidemiological study was conducted by Eriksen et al. (2006) using data
from the 2000 Danish Health and Morbidity Survey. Participants completed interviews
and questionnaires regarding pain, quality of life, health care utilization and satisfaction,
and medication and drug use. Eriksen and colleagues found that those patients
prescribed long-term opioid treatments did not have improved pain relief, quality of life,
or functional ability as compared to other pain patients not receiving medication. This
led the authors to question the utility of broad usage of pain medication for all chronic
pain patients and suggest more selective use. The epidemiological studies reviewed
here provide preliminary concern over the occurrence of prescription misuse in a
chronic pain population, but the large samples needed for these studies inherently
limited the number of predictive factors that could be examined.
The next set of research studies on chronic pain and substance use are point
prevalence studies of prescription misuse and other substance abuse in participants
recruited from chronic pain clinics (Chabal et al., 1997; Fleming, Balousek, Klessig,
Mundt, & Brown, 2007; Hoffman et al., 1995; Morasco & Dobscha, 2008; Reid et al.,
2002). These studies were focused on a smaller participant population, thus allowing
exploration of additional concurrent and predictive factors suggestive of prescription
misuse. Unfortunately, the factors explored in these studies were also limited and
included: age (Fleming et al., 2007; Morasco & Dobscha, 2008), psychiatric comorbidity
(Chabal et al., 1997; Fleming et al., 2007; Morasco & Dobscha, 2008), substance abuse
histories (Chabal et al., 1997; Morasco & Dobscha, 2008), and concurrent abuse of
other substances (Fleming et al., 2007; Hoffman et al., 1995).
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Fleming et al. (2007) assessed 801 patients receiving a daily opioid treatment
regimen from a primary care physician. Medical record reviews and interviews were
used to examine point prevalence (9.7% any substance, 3.8% opioid) of substance use
disorders within this population and it was found that those who abused their medication
were younger, had a higher rate of psychiatric comorbidity, and higher rate of use of
illicit substances. The authors also found that opioid use disorders were four times more
likely within a chronic pain population being treated with opioids than those in the
general population. Chabal et al. (1997) found that 27.6% of their clinic population at a
major VA met at least three of the prescription opioid abuse symptoms determined by
the researchers, such as requesting additional prescriptions or increased dose. The
researchers examined previous history of alcohol or drug abuse and psychiatric history
and found no differences between those who misused opioids and those who did not.
As mentioned above, the concurrent factors explored in the studies described in this
section were limited, but these studies do provide a model for continued exploration of
additional risk factors. Prospective studies allow researchers to determine whether the
factors shown to be associated with substance abuse in chronic pain (psychiatric
comorbidity, age, etc.) can actually predict substance abuse or if those factors are
merely an associated consequence of the substance abuse.
There has been one prospective study of prescription opioid abuse in a chronic
pain population conducted. Ives and colleagues (2006) assessed patients attending a
chronic pain clinic over a one-year period, following urine drug screens and medical
records of requests for additional opioids. They reported age, gender, other substance
misuse, and previous legal involvement as significant predictors of prescription opioid
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misuse, whereas race, socio-economic status, depression and pain were not different
between those who misused their medications and those who did not. The findings from
the point-prevalence studies and the prospective study by Ives et al. (2006) have
yielded different findings. For example, although psychiatric comorbidity was associated
with higher rates of prescription misuse in point prevalence studies, depression was not
related to prescription misuse in the prospective study. Although these differing results
may in part be due to the nature of the methods used (e.g., psychiatric comorbidity may
be shown in point prevalence studies because it is a consequence of substance abuse),
there is a critical need to fully review the existing literature to determine the risk factors
most commonly observed.
In a review of the literature by Turk et al. (2008), the authors call for better
measurements of prescription opioid abuse and use of reliable predictive measures,
stating that the only strong predictor established thus far is a personal history of using
illicit drugs. In a commentary on “The Rational Approach to the Treatment of Chronic
Pain,” Gourlay, Heit, and Almahrezi (2005) expressed the need for physicians to
practice caution and carefully assess all patients for potential abuse, and suggested a
focus on reported past and present prescription misuse behaviors (Gourlay et al., 2005).
Although the sentiment of Gourlay et al. is clear, it seems as though we should be able
to assess variables that actually predict misuse, prior to the occurrence of misuse.
Review of the current state of the literature provided above shows the limited
extent of predictive variables explored within the chronic pain population. It remains
evident that opioid treatment for pain is a necessary treatment for relieving the suffering
of many of those experiencing chronic pain; however, we need more predictive tools to
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identify the groups most at risk for the suffering caused by substance abuse and
addiction. The independent literatures on chronic pain and substance abuse have
addressed substantially more factors than those factors considered in the joint literature
(e.g., expectancies, coping, and emotional factors). It is likely that misuse of prescription
medications or other illicit substance use share common risk variables, such as trauma
history (Logan, Walker, Cole, & Leukefeld, 2002) or emotional regulation factors
(Handelsman et al., 2000; Jensen, Thomsen, & Hojsted 2005; Pinard, Negrete,
Annable, & Audet, 1996) and an exploration of these factors is also necessary.
Although the need for further identification of risks of prescription misuse is
apparent, two primary challenges remain. The first complication that must be addressed
is what additional risk factors should be explored based upon the existing literatures on
chronic pain and on substance abuse. The second complication that must be addressed
is how to identify substance misuse (and particularly prescription misuse) within a
chronic pain population.
Risk Factors
Next, four major areas of literature as related to both chronic pain and risk of
substance abuse will be explored: traditional factors, pain factors, cognitive/social
factors, and emotional factors. Although there is much research addressing each of
these areas within the chronic pain literature and substance abuse literature, there have
been few studies that unify the factors to apply them to substance abuse risk within a
chronic pain population. Relevant studies for each area will be explored below.
Traditional factors such as age, gender, history of substance abuse, and history
of psychological treatment are all factors that are readily available to a physician
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working within a chronic pain population. As noted above (Becker et al., 2008; Blanco et
al., 2007; Compton et al., 2006; Dowling et al., 2006; Edlund et al., 2006; Erikson et al.,
2006; McCabe et al., 2005), these factors have been established as the primary
variables in the exploration of prescription opioid misuse.
Age and gender are two variables often considered within substance abuse
literature. Review of national surveys has found increasing rates of opioid abuse
(Compton & Volkow, 2006) and higher rates of abuse within younger age groups
(Dowling et al., 2006; Fleming et al., 2007; Riley & Hastie, 2008) for both medical and
non-medical abuses of opioids. The National Survey on Drug Use and Health has
reported the highest rates of prescription opioid use amongst adolescents and older
adults (over the age of 60). Gender is another variable that is quickly assessed by
physicians and researchers; however, exploration of its predictive value has been
limited. Most studies have recorded and controlled for gender when exploring opioid
abuse in chronic pain patients for women and men rather than exploring differences.
One study that examined gender differences of substance abuse in chronic pain
patients reported higher rates of abuse among men (Ives et al., 2006).
The most common factor that is quickly examined by physicians prescribing
opioid medications is a patient’s history of prior drug or alcohol abuse. Michna et al.
(2004) reported that past history of alcohol or other substance abuse was one of the
most important factors in determining whether a chronic pain patient is at risk of misuse
of prescription opioids. Michna and colleagues conducted a study to assess who would
abuse prescription opioids, and found those with past history of abuse were more likely
to have aberrant behaviors such as lost or stolen prescriptions or other illicit drugs in
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their urine screens. Additionally, reviews of the literature report personal history of
substance abuse as the only strong predictor that has been reliably assessed and
shown to predict prescription opioid misuse across multiple studies (Compton & Volkow,
2006; Turk et al., 2008). Despite the common use of this prior drug history in
determining whether a patient is at risk of abusing their current prescription, there have
been a few exceptions to this finding. For example, Chabal et al. (1997), in their study of
97 VA patients prescribed opioids for the treatment of chronic pain, found that prior
history of substance abuse did not significantly differ between patients who abused their
opioid prescription and those who did not abuse their prescriptions. Because of
inconsistent evidence for the usefulness of prior history of substance abuse as a
predictor, it is clear that we need to consider other additional factors.
Family history of substance abuse is another common variable considered in the
substance abuse literature; however, research on family history of substance abuse as
a predictor of prescription drug abuse is more limited. Studies that have examined
family history of substance abuse or dependence have found significantly increased risk
of opioid misuse for those with the most extensive family histories (Butler, Budman,
Fernandez & Jamison, 2004; Hojsted & Sjogren, 2007).
History of mental health treatment and/or psychiatric diagnosis has been another
area frequently explored in the literature. Michna et al. (2004) found that chronic pain
patients with higher rates of depression and anxiety were significantly more likely than
others to abuse prescription opioids. Multiple studies have found increased rates of
psychological treatment histories in chronic pain patients who misuse their prescription
opioids (Becker et al., 2008; Lake, 2008; McWilliams, Clara, Murphy, Cox, & Sareen,
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2008; Potter, Shiffman, & Weiss, 2008; Wasan et al., 2007; Weitzner, Cockram, &
Strickland, 2003).
Pain factors. The next area of literature is pain within the context of substance
abuse risk. There is limited research regarding pain as a risk factor for substance
abuse, however, both pain severity and pain coping are factors that physicians are likely
already assessing in their care of chronic pain patients. It makes practical sense that
increased pain severity may lead to increased prescription use. Additionally, as
described previously, the under-treatment of pain, can lead to abuse-type symptoms
such as requests for increased doses or stronger medications, using more of one’s
prescription than advised, and/or dissatisfaction with treatment without there being
additional behavioral concerns of addiction or misuse (Weissman & Haddox, 1989).
Thus, pain severity is a complicated but essential variable to explore when assessing
risk factors in chronic pain patients.
Equally important is one’s ability to cope with pain. One potential area of interest
within the pain coping literature is “pain catastrophizing.” Pain catastrophizing is a belief
in negative, future outcomes of pain experience, and thus often leads to attempts to
avoid or escape pain (Gatchel, Peng, Peters, Fuchs, & Turk, 2007). In a 10-year followup of patients in a chronic pain clinic, Jensen et al. (2005) found that patients who were
prescribed long-term opioid medication treatment had decreased levels of quality of life,
more symptoms of depression, and increased use of the coping strategies of
“catastrophizing” and “hoping and praying.”
Cognitive/social factors. The third category of literature that will be explored is
the category of cognitive and social predictive variables. Few prescription opioid misuse
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studies have utilized these variables; yet, they are among the most commonly explored
risks within alcohol literature (Cooper, Russell, Skinner, Frone, & Mudar, 1992; Tan,
Nyugen, Cardin, & Jensen, 2006). Brown, Christiansen, and Goldman (1987) defined
expectancies in alcohol use through the following categories: that it leads to positive
effects, that it brings pleasure, that it leads to sexual enhancement, that it enhances
social abilities, that it leads to relaxation, and that it leads to aggression/strength.
Scheiffer and colleagues (2005) conducted a study of medication belief in chronic pain
patients using a scale the researchers created based upon patient interviews. The
medication beliefs assessed were: belief the medication would relieve pain, become
addicting, increase functioning, improve affect/feelings, and need for increased
medication. Scheiffer et al. (2005) found that chronic pain patients who reported
previous histories of substance abuse also reported higher levels of beliefs in the
effectiveness of the opioid medications.
Other well-supported and commonly explored variables in the broader substance
abuse

literature

are

neuroticism

and

behavioral

undercontrol

(i.e.,

low

conscientiousness) in alcohol research (Grekin, Sher, & Wood, 2006; Sher, Bartholow,
& Wood, 2000). The construct of extraversion has been shown to have the strongest
relationship with illicit drug use (Agrawal, Jacobson, Prescott, & Kendler, 2004; Gorman
& Derzon, 2002), but the link between extraversion and alcohol use disorders is weaker.
neuroticism and behavioral undercontrol (or low conscientiousness). There are no
published studies that have explored the relationship between neuroticism, behavioral
undercontrol (low conscientiousness), or extraversion and prescription misuse or other
substance use in a chronic pain population.
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Social support has been explored extensively as it relates to substance abuse in
adolescence. Research has found that low levels of perceived and actual social support
in adolescence are related to an increased risk of substance abuse in adolescence and
adulthood (Chaffin, Kelleher, & Hollenberg, 1996; Myers, Brown, & Mott, 1993; Rhodes
& Jason, 1990; Wills & Cleary, 1996; Wills & Vaughn, 1989). Within adult populations,
most social support research has examined its relationship to substance abuse
treatment outcome. Individuals with increased levels of perceived and actual social
support in adulthood are more likely to engage in and complete treatment programs,
have increased help seeking behavior, and maintain their recovery through follow-up
(Aase,

Jason,

&

Robinson,

2008;

Oetzel,

Duran,

Jiang,

&

Lucero,

2007;

Panchanadeswaran, El-Bassel, Gilbert, Wu, & Chang, 2008). Thus, research on social
support has shown that low levels of support predicts substance use onset in
adolescence and lower chances of recovery from substance abuse and dependence in
adulthood.
Emotional factors. Emotional factors are the least explored predictive factor in
the prescription opioid misuse literature. This final category of predictive factors is the
most difficult to assess, but the research within the two independent fields has provided
rich explanations to some of our most perplexing questions of human experience. The
concept of “self-medication” within the substance abuse literature also provides reason
for exploring emotional factors within the context of prescription medication misuse. The
“self-medication” concept was created primarily through clinical observations of patients
in treatment for substance abuse. Khantzian (1997) describes a person’s attempt at
self-regulation of uncomfortable or painful experiences of affect, self-esteem, and
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relationships. As the term suggests, in this model, substances are used to mask or
avoid these uncomfortable or painful affective and/or relational experiences.
Additionally, there is a large body of research in the alcohol literature that has examined
the motive to use alcohol to manage stress and emotions (Cooper, Frone, Russell, &
Mudar, 1995) that suggests that people who regulate their emotional experiences
through the use of alcohol are more likely to develop abuse symptoms. There is some
research to suggest that emotion regulation based motives to use nonmedical
prescription drugs (e.g., nonprescribed sedatives, opioids, stimulants) are also
associated with higher rates of abuse (McCabe, Boyd, & Teter, 2009). Despite the
prevalence of this model within clinical practice, emotional regulation factors have been
largely ignored within the literature on prescription misuse in chronic pain patients.
Experience of stressful or traumatic events has been linked to both the presence
and severity of chronic pain conditions (Green, Flowe-Valencia, Rosenblum, & Tait,
2001; Finestone et al., 2000; Sachs-Ericsson, Kendall-Tackett, & Hernandez, 2007) and
substance abuse and dependence (Logan et al., 2002; Wilsnack, Vogeltanz, Klassen, &
Harris, 1997). Finestone and colleagues (2000) found that childhood sexual abuse is
positively related to chronic pain. Research has also suggested that individuals with
past traumas are more likely to abuse substances. Wilsnack and colleagues (1997)
used a national survey that assessed childhood sexual abuse and use of substances
and found that those women who experienced childhood abuse were significantly more
likely to abuse alcohol and other illicit substances. In a review of the literature on
substance abuse and trauma histories, Logan and colleagues (2002) reported a high
rate of co-occurrence of trauma and substance abuse and dependence in women. The
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researchers developed a complex model suggesting that the relationship between
trauma and substance abuse in women can be explained by trauma and coping factors,
lifestyle factors, sociological factors, and contextual factors. Uniting the chronic pain and
substance literature, Green and colleagues (2001) studied women presenting for
chronic pain management and found that nearly half had experienced trauma, and
those with long-term abuse had higher incidence of substance abuse.
A person’s general approach to coping with emotions can have a substantial
impact on their psychological and physical functioning. In general, emotionally focused
coping has been shown to lead to a variety of deleterious outcomes. However, one
specific type of emotionally focused coping, emotional approach coping, has been
shown to actually predict better outcomes in a variety of studies (Austenfeld & Stanton,
2004; Smith, Lumley, & Longo, 2002). Previous research has also shown that within a
chronic pain population, emotional approach coping specifically may lead to decreased
pain and depression (Smith et al., 2002). Emotional approach coping is the tendency of
a person to understand and process or use emotions throughout one’s daily life.
Emotional approach coping is one’s general approach to dealing with emotional
information in their life. Because we know that emotional approach coping leads to
decreased pain and depression (Smith et al., 2002), both of which we have reason to
predict relate to prescription misuse and substance abuse, emotional approach coping
is an important variable to explore.
Alexithymia is a widely researched emotional regulation concept which is defined
as difficulty indentifying and describing feelings, externally oriented thought and limited
imaginal ability (Nemiah, Freyberger, & Sifneos, 1976; Taylor, Bagby, & Parker, 1997).
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Although alexithymia was originally studied in people with psychosomatic disorders,
research shows it to be a risk factor for many problems, including chronic pain and
substance dependence (Taylor et al., 1997). Recent research has begun to connect the
experience and maintenance of chronic pain with alexithymia (Ak, Sayer, & Yontem,
2004; Burba et al., 2006; Celikel & Saatcioglu, 2006; Lumley, Neely, & Burger, 2007).
There have been no published studies relating alexithymia to prescription drug misuse
in chronic pain patients; however, there has been some research on the relationship of
alexithymia to other drugs of abuse (Handelsman et al., 2000; Pinard et al., 1996).
Pinard and colleagues (1996) examined the alexithymia scores on the Toronto
Alexithymia Scale-20 (TAS-20) at baseline in a drug treatment center and found that
patients attending drug treatment had significantly higher scores on the TAS-20 than
non-patients. The researchers also repeated the TAS-20 at completion of treatment and
found no significant differences from baseline to treatment completion, suggesting that
alexithymia is relatively stable within this group and is likely not a direct effect of active
substance use.
Further, emotional regulation techniques have also been linked to chronic pain
and coping with pain (DeGenova, Patton, Jurich, & Macermid, 1994; Leitenberg,
Greenwald, & Cado, 1992). The two primary regulation techniques that have been
explored are avoidant and emotion focused coping which may lead to increased pain
symptoms, emotional distress, and general negative outcomes. Although emotional
regulation techniques have been suggested as a factor in substance abuse through the
“self-medication” model, there have been no published studies exploring avoidant and
emotion focused coping directly. Theoretically, within the “self-medication” model, it
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would seem as though individuals who engage in avoidant coping techniques may be
more likely to engage in substance abuse behaviors as an escape process, but there is
no current literature to support this claim.
In addition to our lack of an operational definition of prescription misuse and
mixed results regarding predictive factors of prescription misuse and other substance
use in a chronic pain population, our understanding of this serious problem is also
limited by our ability to collect accurate information in both research and clinical
settings. Gathering accurate self-report of a stigmatizing behavior such as prescription
misuse or other substance abuse can be challenging. The researcher or clinician must
develop methods to overcome the many motivations that prevent people from sharing
these behaviors (e.g., being looked down upon, decreasing their chances of receiving
prescription medications, being unaware that their behavior could be problematic).
Disclosure of Stigmatized Behaviors
Disclosure of stigmatized behaviors in research, and specifically drug use,
requires a balance of the researcher’s need for reliable, and consistent information with
a participant’s comfort in sharing based on beliefs of confidentiality, trust in the
researcher, and clear understanding of the questions being asked. Under-reporting in
studies of drug use has been a long documented problem (Andrews, Kendler, Gillespie,
& Neale, 2007; Booth-Kewley, Larson, & Miyoshi, 2007; Fendrich, Wislar, & Johnson,
2003). Of particular interest in understanding the accuracy of self-reported of misuse of
prescription opioid medications, it has been found that people who face potential legal
or social consequences from reporting their substance use provide less accurate
reports (Golub, Liberty, & Johnson, 2005; Grekin et al. 2010). As reporting misuse
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symptoms related to prescription opioids could potentially lead to the discontinuation of
treatment at many clinics, the motivation to conceal use is likely high. The unreliability of
self-report has led many researchers to examine physiological measures of substance
use such as urine drug screens or hair tests; however, such tests can not assess the
behavioral attributes of abuse or dependence symptoms (Schuckman, Hazelett, Powell,
& Steer, 2008). There is a need to continue improving our methods of increasing selfreport of both misuse of prescription medications and use of illicit drugs and alcohol, as
the most serious consequences of use are behaviors and desires that can only be
reported through the participant.
Disclosure in health care settings involves further barriers to accurate self-report
of symptoms and behaviors because of the potential impact it may have on the doctorpatient relationship. Studies have examined the role of explicit discussion over
confidentiality of medical information. Parrot, Duncan, and Duggan (2000) explored the
literature on patient “impression management” and the impact this has on a caregiver’s
ability to obtain sensitive or stigmatizing behaviors. The authors concluded that it is a
delicate process that requires attention to “organizational, cultural, personal, and
interactional strategies.” A patient may have concerns about requesting additional
medication even when needed, because of fears of appearing as though they are
misusing medications. Patients may also want to appear healthier so that a physician
will reduce restrictions, continue current medical care, and in some instances avoid
concerns about prescription use.
Schuckman et al. (2008) conducted a 6-year record review of patients who came
to the emergency department seeking pain medications. The researchers examined the
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patients’ self-reported drug use and compared it to a drug screen that same day. In
analyses conducted to characterize the difference between people whose self-report
matched the drug screen (68%) and those whose self-report did not match the drug
screen (32%), it was found that individuals with a history of chronic pain or drug abuse
were significantly more likely to have inaccurate self-reports. Reinhard et al. (2007)
found that individuals who were more inaccurate with their self-reported stimulant use
were also less likely to report symptoms of psychopathology. Taken together, these two
studies (Reinhard et al., 2007; Schuckman et al., 2008) provide evidence that selfreported use of substances is often inaccurate. These two studies also show that in
chronic pain populations there may be additional reasons for concern about the
accuracy of reports and that individuals who are more likely to conceal substance use
may also be more likely to conceal other psychological symptoms. In clinical settings,
biological drug tests may not always be convenient or cost-effective and the common
inaccuracy of self-report provides further reason to improve our methods for increasing
the accuracy of self-report.
Another topic that is often under-reported is the experience of trauma. Research
has shown that disclosure of traumatic experiences can be increased by a participant’s
perceived sensitivity of the researcher and the belief in confidentiality of the disclosed
information (Denov, 2003; Leibowitz, Jeffreys, Copeland, & Noel, 2008; Mueller,
Moergli, & Maercker, 2008).

Because the experience of traumatic or stressful

experiences can have such a significant impact on one’s physical and mental health, in
addition to quality of life, it is essential that we continue to develop means to best
identify individuals with trauma histories so that treatment and prevention efforts can be
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targeted towards them. Rosenbaum and Langhinrichsen-Rohling (2006) reviewed the
literature on disclosure of trauma and found the two main factors to consider in
participant disclosure are “willingness to disclose” and “accuracy of disclosure,” both of
which should be considered in any research study. Additionally, the authors call for all
researchers assessing sensitive or stigmatizing information to work to improve research
methodologies to improve internal and external validity of our studies.
There has been recent interest on how to improve self-report of stigmatized
behaviors in research studies and in medical offices. Much of the research has focused
on the evaluation of new technologies to improve self-report (Booth-Kewley et al., 2007;
Joinson, Woodley, & Reips, 2007). Computerized measures have been created for
assessing substance abuse, risky sexual behaviors, and HIV risk behaviors. Most
research has shown increased rates of disclosure of stigmatized behavior using
methods that provide the participant the most distance from the researcher (e.g.,
telephone screens, computerized measures). Additionally, some research has
suggested that spoken disclosure in the presence of another individual may actually
inhibit emotional expression (Newman et al., 2002), possibly making participants more
self-conscious of what they are disclosing and making them feel as though they may be
judged for their disclosure.
Interestingly, with all of the attempts to improve participant reports through
technology, there have been limited attempts at improving the interviewer’s
methodology. The therapy literature suggests that techniques such as metacommunication about relationship factors and about comfort sharing can improve
alliance and ultimately increase disclosures. Recent research within the emotional
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disclosure literature suggests that an active and engaging facilitator may lead to
increased degrees of engagement and disclosure. However, the ability of these
techniques to improve self-report of substance abuse and traumatic or stressful
experiences in research settings has not been explored. Next, therapy and emotional
disclosure literatures will be explored.
Social versus non-social sharing and characteristics of the participant-facilitator
relationship may both have an effect on the content quality of the disclosure session.
Social versus non-social sharing has been examined by comparing private writing tasks
to socially disclosing to a researcher. Newman et al. (2002) compared the degree of
disclosure of potentially stigmatizing events among individuals who had presented to a
syringe exchange program. In this study one group was asked to type their disclosures
on a computer program, whereas another group was asked to disclose in a face-to-face
interview. It was found that individuals were most likely to disclose more information
privately than face-to-face.
In addition to characteristics of the sharing person and his/her experience,
facilitators can vary in their responses. Psychotherapy theory and practice suggests a
continuum of therapist responses. On the one hand, therapists can be either supportive
and non-directive, by using techniques such as active listening, reflection, and following.
Alternatively, they can be more active, working to facilitate disclosure and processing by
questioning,

exploring,

and

encouraging

experiential

exercises.

Research

by

Laurenceau, Barrett, and Pietromonaco (1998) suggests that in interpersonal
disclosures, the responsiveness of the therapist may increase participant’s feelings of
intimacy in the relationship and thus lead to more disclosure. Responsiveness of a
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therapist may involve both verbal (e.g., reflections, guiding questions, etc.) and
nonverbal (e.g., body posture, head nods, facial expression) signs displayed by the
listener, showing interest and concern to the discloser. Based on this study, it is unclear
whether different methods of responsiveness by the therapist may provide the most
appropriate interaction for the highest degree of disclosure and emotionality.
A recent study by Sander et al. (2008) examined four forms of disclosure (i.e.,
writing privately, talking privately, talking with a “passive” facilitator, and talking with an
“active” facilitator) to explore which method leads to the most disclosure in a brief, 30minute session. In all four conditions, the participants were provided with the same set
of instructions regarding what they should disclose during the session. The “passive”
facilitator was supportive and engaged, but did not encourage further disclosure through
questioning and did not meta-communicate about the session. The “active” facilitator
began the session by meta-communicating about the concerns the participant may have
about disclosing, encouraged further exploration of missing emotions or facts about
their experience, and normalized thoughts and feelings about the experience. The
findings suggest that people can be “pushed” further by an “active” facilitator in both
emotional engagement and cognitive processing, but may actually be inhibited by a
“passive” facilitator. Individuals who have experienced stressful or traumatic
experiences seem very capable of being pushed for more disclosure and more
emotional involvement in session.
Most self-report data gathered in previous studies of the accuracy of self-report
have typically used the “passive” facilitator method. The findings of Sander et al. (2008)
suggest that the “passive” model may lead to inhibition and discomfort in the method.
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The typical use of a “passive” facilitator in clinical interviews may explain why research
has suggested that interpersonal methods have not worked as well as computerized
methods for gathering information about stigmatized behaviors. The model of “active
facilitation” described in Sander et al. (2008) may also lead to increased disclosure of
stigmatized behaviors such as substance abuse; however, this has not been explored in
the literature. As described previously, medical settings inherently create additional
barriers to accurate disclosure of prescription misuse and substance abuse because of
the potential impact on their care. The process of meta-communication and
normalization of the worries about sharing drug use may help ease some of those
concerns and increase accuracy of self-report.
Goals and Hypotheses
The current study sought to develop a model of predictive factors in which the
traditional factors, pain factors, social/cognitive factors, and emotional factors each
explain unique portions of variance in the misuse of prescription medication, alcohol and
other substances in a chronic pain population. As most of the previous research has
been conducted using convenience samples and record reviews, there have not been
studies that bring together each of these key variables into a single population of
patients. Patients attending a local chronic pain clinic were assessed for each of these
key variables and for symptoms of prescription medication misuse and use of alcohol
and illicit substances at a single evaluation session. In addition, to bring together all of
the previously explored key variables in the literature, this study also sought to explore
emotional factors as they relate to prescription opioid misuse in chronic pain patients.
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The emotional factors of alexithymia, emotional approach coping, and the experience of
trauma were explored.
This study also tested different methods of data collection that may increase the
self-reported sensitive information of prescription misuse, substance abuse or
dependence, and experience of stressful or traumatic experiences. Much of the
previous research regarding assessment of stigmatized or sensitive information has
explored computerized methods to increase distance and beliefs of confidentiality
between the researcher and the participant. In the current study, a novel interviewer
procedure was designed to facilitate discussions of confidentiality and metacommunication about the interviewer-participant relationship and the sensitivity of the
information the participant is being asked to report. Three methods of data collection for
substance use and trauma history were tested: enhanced interviewer, standard
interviewer, and questionnaires.
Overall, this study had three goals: a) develop a model of predictive factors for
chronic pain patients, bringing together the variety of factors that have been explored
independently in previous studies; b) add emotional factors to the predictive model to
assess whether these factors can explain unique variance beyond the traditionally
explored variables: and c) develop and experimentally test methods by which the most
sensitive information is disclosed by participants.
Concurrent Predictors of Prescription Drug Abuse
Aim 1. Determine which demographic, pain-related, cognitive/social, and
stress/emotional factors predict prescription misuse and abuse and dependence
symptoms for prescription opioids among patients in treatment for chronic pain.
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Hypothesis 1. It was predicted that higher levels of prescription misuse and
symptoms of abuse and dependence would be associated with younger age,
lower

social

support,

previous

history

of

psychiatric

diagnosis,

high

catastrophizing of pain, high expectations for the effects of the prescription, high
extraversion, alexithymia, high levels of emotional ambivalence, and low levels of
emotional approach coping.
Aim 1a. Test whether factors related to stress and emotion regulation (low
emotional awareness and expression, high experience and impact of lifetime
trauma) predicted prescription misuse beyond more routinely assessed and
established factors.
Hypothesis 1a. It was hypothesized that a model building in emotional variables
can increase the predictive ability of common medical belief of who might be at
greater risk of showing abuse characteristics with prescription opioids and with
the use of other substances. Specifically, it was predicted that higher levels of
alexithymia, lower levels of emotional approach coping, and more experience of
trauma and impact of trauma will explain additional variance predicting
concurrent prescription misuse and abuse and dependence symptoms for
prescription opioids, as measured by the PDUQ, beyond traditional, pain, and
cognitive/social factors.
Aim 2. Determine which demographic, pain-related, cognitive/social, and
stress/emotional factors predicted use of alcohol and illicit substances among patients
in treatment for chronic pain.
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Hypothesis 2. It was predicted that higher levels of alcohol and illicit substance
use will be associated with younger age, lower social support, previous history of
psychiatric diagnoses, high catastrophizing of pain, high expectations for the
effects of the prescription, high extraversion, alexithymia, and low levels of
emotional approach coping.
Aim 2a. Test whether knowledge of factors related to stress and emotion
regulation (low emotional awareness and expression, high experience and
impact of lifetime trauma) predicted alcohol and illicit substance beyond more
routinely assessed and established factors.
Hypothesis 2a. It was predicted that higher current levels of alcohol and other
illicit drug use would be associated with higher levels of alexithymia, lower levels
of emotional approach coping, and more experience of trauma and impact of
trauma, beyond traditional, pain, and cognitive/social factors.
Methods of Disclosure of Stigmatized Information
Aim 3. Determine whether variations in assessment methods lead to differing
amounts of disclosure of aberrant use of prescription drugs, use of alcohol and other
drugs, and trauma history.
Hypothesis 3. It was predicted that higher reported misuse of prescription
medication, use of alcohol and illicit drugs, and experience of stressful events or
traumas would occur in the following order: enhanced interview (highest), written,
standard interview (lowest).
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CHAPTER 2
METHODS
Participants
Participants were 100 patients with chronic pain who were receiving treatment
through a local pain management clinic. All participants reported chronic pain for at
least 3 months prior to study participation and were prescribed a self-administered
opioid at the time of assessment. Participants were excluded from the study if they
reported non-literacy in English and/or they were not actively receiving treatment
through the pain management clinic at which all recruitment occurred. Participants were
recruited from August 2009 through November 2010.
A total of 103 participants met criteria and came to the laboratory or the pain
clinic for their study visit. Of the 103 participants who started the study, 100 (97%)
completed the full session and were included in analyses. An additional 23 people met
study criteria and scheduled a study visit, but did not attend their session.
Approximately 20 people who called the laboratory stating that they were interested in
participating did not meet study criteria, and the primary reasons were that they were
not attending the pain management clinic through which the study recruited or they
were not currently prescribed an opioid. In the final sample of 100 participants, 47%
were male and 53% were female, and the sample had an average age of 47.57 years
(SD = 11.57). The sample was predominantly African-American (81.0%), with other
participants identifying as Caucasian (11.0%), or other (3.0%), and a small portion
chose not to disclose their ethnicity (5%).
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Procedure
Participants were recruited through pamphlets provided in the clinic waiting room
of the pain management clinic (see Appendix A). The pamphlets included a brief
description of the study and provided a phone number at which study personnel could
be reached to provide further information regarding the study. Additionally, study
personnel approached participants in the waiting room of the pain clinic and provided
information to interested patients. The study personnel recorded phone numbers of
patients who requested to be contacted for an appointment. More than half of the
participants approached reported interest in receiving more information and possibly
participating in the study. Of those participants who did not report interest in
participating, the most common reasons were: no interest in being in any research
study, limited time or transportation, and knowing that they did not meet criteria (e.g.,
first session at the clinic).
All potential participants were contacted via phone and provided more
information about the study and protocol (See Appendix B). Patients were then
scheduled for a study visit at a time convenient to them either at the laboratory or the
pain management clinic. Participants were called the day prior to their scheduled study
visit to remind them of the date and time of their session.
Study visits were conducted in private rooms to ensure privacy of the participant,
and the physicians were not allowed access to an individual participant’s data. Upon
arrival to the study visit, the participant was greeted by the researcher and provided the
information sheet in lieu of consent approved by the Wayne State University Human
Investigation Committee (Appendix C). The researcher reviewed the information sheet
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with the participant and answered any questions the participant had at that time. Upon
review of the study with the Human Investigation Committee, it was determined that if
participants reported misuse of their medications and the researchers were aware of the
patients’ names, we would be required to inform their clinicians at the pain management
clinic of their misuse. Thus, the information sheet was provided as an alternative to a
signed informed consent form to maintain anonymity of participants because it was
believed that it would interfere with the study if disclosure of medication misuse and/or
drug use would lead to potential consequences such as discharge from their pain
management program. After the consent process, the participants began the nonrandomized portion of the study, completing paper-and-pencil questionnaires.
The first portion of the evaluation was identical for all participants. All participants
completed multiple questionnaires in paper-and-pencil format regarding demographic
information, alexithymia, pain disability, mood, and emotional expression. Participants
were then randomized into one of three groups. The researcher opened a sheet of
paper which was stapled to the back of the participant folder to reveal the participant’s
group (group assignments are described below in “Experimental Groups”). Participants
then engaged in one of the three, randomized, information-gathering formats for the
remainder of the evaluation, which included information on trauma, prescription misuse,
and alcohol and other drug use. The final measure was written, and private for all
groups, which was ratings of their comfort with the method of assessment that they
engaged in and the degree to which they were able to be open about their substance
use and stressful life events. The entire study session lasted approximately 1.5 to 2
hours. At the completion of their visit, participants were compensated $30 for their
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participation in the study and provided a list of local mental health treatment facilities,
substance abuse treatment facilities, and emergency hotlines.
Experimental groups. After completing the informed consent process,
participants first completed the non-randomized paper and pencil questionnaires
privately. Participants were then randomized to one of the three groups to complete the
measures of potentially stigmatizing information (i.e., substance use, medication
misuse, and experience of trauma). The three groups were as follows: written, standard
interview, and enhanced interview. Participants were randomized into one of the three
conditions in blocks of 6 (resulting in equal numbers of patients in each group after
multiples of six), using a random number sequence generated by a computer
(randomization.com). The randomization list was stratified by patient gender and by
researcher/interviewer. After the initial paper and pencil questionnaires, two of the three
groups met with an interviewer, who was a graduate student in clinical psychology,
while the other group was written and completed in private. The randomized portion of
the evaluation lasted approximately 30 minutes. At the completion of the randomized
portion of the session, the participant then completed the final session evaluation.
Written evaluation. Participants assigned to the written evaluation completed all
portions of the study on paper and pencil questionnaires. After completing the predictor
measures, the researcher returned to the room and collected those measures. The
researcher then provided the participant the trauma and substance use forms, briefly
explaining the scales used on each, and then allowed the participant to complete the
forms in private. These participants completed assessments of traumatic and stressful
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experiences, evaluation of current and past use of alcohol and illicit substances, and
prescription misuse in written format.
Standard interview evaluation. These participants spoke to a standard
interviewer. The questions were identical to those in the written format, but were read
aloud to the participant by an interviewer. Participants randomized to this group
completed assessments of traumatic and stressful experiences, evaluation of current
and past use of alcohol and illicit substances, and prescription misuse portion of the
evaluation with the interviewer. The interviewer was attentive, empathic, but passive,
simply asking the structured questions and recording the participant’s responses to
each of the listed questions. The interviewer was able to respond to any concerns the
participant may have had about specific questions, identical to the way they would have
responded to concerns of participants in the written evaluation group. In this condition
the interviewer was attentive to the participant but did not provide any prompts to
explore further the emotions or facts, nor did the researcher meta-communicate about
the session. The interviewer guidelines for this condition are in Appendix D. The
structured interview questions were identical to those used in the Enhanced Interview
group (described next).
Enhanced interview evaluation. The participants assigned to this group spoke
to an enhanced interviewer for the assessments of traumatic and stressful experiences,
evaluation of current and past use of alcohol and illicit substances, and prescription
misuse. The questions for this group were again identical to the two previous groups.
However, in this group the interviewer was an active part of the process of gathering
information. The interviewer began this portion of the session with meta-communication

41
about confidentiality of the interview and normalizing the occurrence of prescription
misuse and substance use and concerns that they might have about sharing personal
information with someone that they do not know. In this condition, the interviewer also
engaged in follow-up questions when information seemed contradictory or unclear
during the interview. The interviewer also encouraged continued disclosure if the
participant seemed hesitant or nervous about providing answers to specific questions.
The interviewer tried to identify missing content in the participant’s responses and
encouraged further exploration of these areas, while also returning to metacommunication about the session and/or interviewer-participant relationship when it
seemed necessary. At the beginning of this portion of the session and at specified
points during the questioning, the interviewer followed a script designed to normalize
the experience of these potentially stigmatizing behaviors and validate their concerns
about sharing these behaviors. The interviewer expressed understanding of the concern
the participant may have in sharing prescription misuse, substance abuse, or trauma,
while also encouraging them to provide honest responses. The enhanced interviewer
guidelines are in Appendix D. After completing either of the interviewer conditions, as a
manipulation check, participants answered a brief questionnaire regarding the degree to
which the interviewer encouraged them to share.
Measures
As stated previously, the purpose of this study was two-fold. The first purpose of
this study was the development of a model using four main areas of interest for
predicting abuse of substances, including prescription drugs. The four main areas were
traditional information (e.g., sex, age, family history of abuse, psychiatric symptoms),
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pain factors (e.g., severity, pain coping), social/cognitive factors (e.g., social support,
expectancies, personality), and emotional factors (e.g., trauma, alexithymia, emotional
coping styles). The scales used to assess each of these areas are described below.
The final section of measures is the outcome measure of current misuse of prescription
drugs and other substances. Measures assessing the participants’ reactions to each of
these three groups will also be described below.
Traditional Information
The traditional information gathered was sex, substance abuse history of any
drug, parental substance abuse, length of time in treatment, and mood/anxiety
symptoms. This information was collected through a paper survey developed by the
researcher. These are traditional pieces of information that can be gathered on a
doctor’s visit which may or may not lead to a physician’s perception that the individual is
at risk for abusing his or her prescription pain medication.
Psychiatric symptoms. Psychiatric symptoms were assessed using the Brief
Symptom Inventory (BSI; Deragotis, 1975). The BSI consists of 53 items, each of which
is rated on a 0 (not at all) to 5 (extremely) scale corresponding to how much they have
been distressed about each symptom over the past 7 days. There are 9 subscales and
3 global indices which assess distress over symptoms and experience of symptoms
broadly: Global Severity Index (GSI), Positive Symptom Distress Index, and Positive
Symptom Total. Other dimensions that can be analyzed are as follows: Somatization,
Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic
anxiety, Paranoid ideation and Psychoticism. The GSI is the most broadly used
composite score and has good test-retest reliability (Deragotis, 1993) and validity
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(Conoley & Kramer, 1989; Derogatis, Rickels, & Rock, 1976). Only the GSI was
analyzed for the purpose of the current study. The GSI was highly reliable for this
sample (α = .98).
Pain Information
The pain information that was gathered was used to assess both pain severity
and pain coping.
Pain severity. Pain severity was assessed by the Brief Pain Inventory (BPI)
which was developed by the Pain Research Group (Daut, Cleeland, & Flanery, 1983). It
includes two scales: pain severity and pain interference. Only the pain severity total was
used for analyses. All items of the BPI are rated on a 0 to 10 rating scale, and ask
responders to rate how their pain is at that moment in time, and the worst, least, and
average over the past week. The BPI is used widely to assess functioning across
various pain problems. The BPI had an acceptably high internal reliability in this sample
(α = .83).
Pain coping. Pain coping was assessed by two measures. The first pain coping
measure was the Pain Catastrophizing Scale (PCS; Sulllivan, Bishop, & Pivik, 1995).
The PCS is a 12-item scale used to assess rumination, magnification, and helplessness
from pain, with alphas of .87, .60 and .79 respectively (Sullivan, et al., 1995). Sullivan et
al. (1995) found that people scoring high on this scale had higher levels of emotional
distress and increased thoughts about and intensity ratings of pain. Sullivan et al.
(1995) also found that the PCS significantly correlates with pain intensity, beyond
measures of negative affectivity and emotional distress. The full scale of the PCS was
used in this study, and it had high internal reliability (α = .93).
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The second pain coping measure used was the Pain Anxiety Symptom Scale
(PASS), which was originally developed by McCracken, Zayfert, and Gross (1991). The
PASS has been shown to have good internal consistency and validity (McCracken,
Zayfert, & Gross, 1992). The internal consistency was found to be high in this sample
(α = .94). The Pain Anxiety Symptom Scale-Revised (PASS-R; McWilliams &
Asmundson, 1998) was used in this study. The PASS-R consists of the following
subscales: Interference, Approach Behaviors, Catastrophic Thoughts, Monitoring and
Prevention, and Physiological Arousal. The PASS-R Total score (PASS-TOT) was
analyzed for this study.
Cognitive/Social Factors
For this domain, social support, expectancies, and personality were assessed.
Social support. Social support was assessed using the Social Provisions Scale
(SPS; Cutrona & Russell, 1987). The SPS consists of 12 items and can be divided into
the following six subscales (four items each): Attachment, Social Integration,
Reassurance of Worth, Reliable Alliance, Guidance, and Opportunity for Nurturance.
The SPS can also produce a Global Social Support score. The SPS has been used
widely as a measure of support in stressful or emotionally challenging events such as
dealing with an illness, taking care of sick relatives, and even for stressful employment
experiences. The Global Social Support score was used for the purpose of our
analyses, and it was found to have an acceptably high internal reliability for a research
measure (α = .74).
Beliefs. Pain medication beliefs were assessed using an opioid medication
beliefs scale developed by Schieffer et al. (2005). As the scale was designed for
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descriptive purposes, one item from the scale was chosen to represent pain medication
beliefs. The item used was a rating of how much medication the participant felt they
needed compared to other pain patients: none at all, a little, about the same, a little
more, or much more.
Personality. Personality factors were assessed using the Ten Item Personality
Inventory (TIPI; Gosling, Rentfrow, & Swann, 2003) which assesses Openness,
Conscientiousness, Agreeableness, Emotional Stability (reverse of Neuroticism), and
Extraversion. As the name suggests, the TIPI consists of 10-items rated on a scale of
1(strongly disagree) to 7(strongly agree), regarding how much they believe that the
statement applies to him or her. Each subscale consists of two items.
Emotional Factors
Emotional factors that were examined for this study were stress symptoms and
emotional regulation measures.
Stress symptoms. The Impact of Events Scale was originally developed by
Horowitz, Wilner, and Alvarez (1979) to assess subjective distress as a result of
traumatic experiences. The Impact of Events Scale includes subscales for Avoidance,
Intrusions, and a Total score. The Impact of Events Scale-Revised (IES-R; Weiss &
Marmar, 1996) was used for the purpose of this study which includes the additional
scale of Hyperarousal. The IES-R contains 22-items which are based upon the DSM-IV
symptoms of PTSD. Each item is rated on a 0 (not at all) to 5 (extremely) scale
regarding how bothered they have been by each symptom over the past 7 days.
Because the participants who were recruited into the study had not all experienced a
traumatic event as defined by the DSM-IV, the introduction to this scale was modified to
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include a broader conception of stressful experiences. The IES Total Score was highly
reliable in this sample (α = .95).
Alexithymia. The Toronto Alexithymia Scale-20 (TAS-20; Bagby, Parker, &
Taylor, 1994) assesses global alexithymia, and three additional facets of alexithymia:
difficulty identifying feelings, difficulty describing feelings, and externally oriented
thinking. The scale has good reliability and is the most extensively validated measure
of alexithymia (Bagby, Taylor, & Parker, 1994). Because the three subscales of the
TAS-20 appear to have differential validity and tap different aspects of emotional
regulation, the subscales were analyzed as well as the total score (α = .80) for this
study.
Emotional ambivalence. To assess the experience of desiring to express
emotions and conscious inhibition of expression, the Ambivalence Over Emotional
Expression Questionnaire (AEQ; King & Emmons, 1990) was used. The AEQ has high
reliability and also predicts negative mood and physical symptoms better than measures
assessing the frequency of expressing emotion (King & Emmons, 1990). This study
used a 14-item short version of the scale, which had high internal reliability for the AEQ
total score (AEQ-TOT; α = .90).
Tendency to seek emotional support. The 8-item Emotional Approach Coping
scale (EAC; Stanton, Danoff-Burg, Cameron, & Ellis, 1994) assesses emotion-oriented
coping. The EAC contains two subscales: emotional processing (seeking to understand
and identify emotions) and emotional expression (expressing adaptive emotions). This
scale has good internal consistency and validity (Stanton, Kirk, Cameron, & DanoffBurg, 2000; current sample: α = .85).
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Outcome and Potentially Stigmatizing Measures
There were two outcomes for this study, which coincide with the two primary
goals. The first goal of this study was to develop predictors for concurrent substance
abuse and specifically abuse of prescription opioids. The area of outcome for this goal
was the substance use measures that are described in this section. The second goal of
this study was to test whether participants shared different levels of stigmatized
information as a function of the group to which they were assigned (private, traditional
interview, enhanced interview). The areas of outcome for this goal were again the
substance use measures and disclosure of stressful life events.
Stressful life events. The Life Stressor Checklist-Revised (LSC-R; Wolfe,
Kimerling, & Brown, 1993; Wolfe, Kimerling, Brown, Chresman & Levin, 1996) consists
of 30 items assessing DSM-IV-TR criteria events for PTSD, in addition to non-DSM
stressful life experiences. The items that describe PTSD life events include questions
about the participant’s perception of harm or lethality, the intensity of their emotional
reaction, and how much the event has affected them during the past year. The nonPTSD questions ask about how much the stressful experience has affected the person
over the past year. The LSC-R has demonstrated criterion-related validity for PTSD
individuals with comorbid substance abuse and other psychological disorders (McHugo
et al., 2005; Wolfe & Kimmerling, 1997). The number of PTSD life events and the
degree of distress participants continue to feel from these events was analyzed from
this measure. Total number of events was calculated based on the number of the 30
possible events that the participant endorsed as having experienced. Level of distress
was calculated by averaging the current distress felt for each event (0- none at all to 5 –
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extreme) across the events he or she experienced. This measure was part of the
experimental portion of this study in that one-third of the participants filled this form out
in the traditional written format. The other two-thirds of the participants were interviewed
using this measure (a non-traditional method for use of this measure).
Substance use, abuse and dependence. Use, abuse, and dependence on
alcohol, prescription opioids, and other drugs were assessed using the Structured
Clinical Interview for the DSM-IV-TR (SCID; First, Spitzer, Gibbon, & Williams, 2002;
DSM-IV-TR: Diagnostic and Statistical Manual, version IV, text revision). Participants
were randomized into one of the three groups to complete these measures.
Prescription misuse. Prescription misuse was assessed using the Prescription
Drug Use Questionnaire (PDUQ; Compton, Darakjian, & Miotto, 1998) as it provided the
most comprehensive list of misuse symptoms and also has been developed to be used
in either an interview or written format. The PDUQ consists of 31 items which address
prescription misuse behaviors such as use of the medication to treat non-medically
prescribed symptoms, doctor’s refusal to prescribe medication, disagreements with
significant others over their prescription use, etc. The PDUQ has shown good testretest reliability and criterion and predictive validity in chronic pain populations. The
PDUQ has been shown to predict patients who later violate clinic policies related to
prescription use and are forced to leave their treatment centers because of these
violations (Compton, Wu, Schieffer, Pham, & Naliboff, 2008). The internal reliability of
this measure for this sample was acceptably high for research purposes (α = .71).
Evaluation of session. Participants were asked to rate items on a 1 to 7 scale,
regarding their evaluation of their comfort sharing, the degree to which they withheld
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sensitive information about trauma or substance use, and comfort with their interviewer
(if they were in the standard or enhanced interview conditions).
Data Analyses
The data were checked for accuracy and frequency distributions of all items, and
scored variables were examined for outlier values. Key missing data points were
replaced through regressions using available measures. Skewed and outlier variables
were transformed. The GSI was positively skewed and a log transformation successfully
reduced the skewness. The SPS was skewed negatively and had a single low outlier.
Inverse and log transformations were unsuccessful and thus the outlier was changed to
the next lowest value in the dataset which successfully reduced the skewness. Finally,
the BPI had a single high outlier and log transformations and square root
transformations were unsuccessful in reducing it, the highest value was changed to the
next highest value. The data was rechecked for skewness and kurtosis after all
transformations and changes to the dataset. Internal consistency was assessed for all
scales and reported in the description of each measure. Finally, the data was assessed
for multicollinearity and the highest correlation between predictors was r = .65 (TASTOT and AEQ-TOT), which is below the r = .70 cut-off suggested by Tabachnick and
Fidell (2001) for multicollinearity in multivariate statistics (see Tables 4 and 5).
Hypothesis 1. Hierarchical regressions were run to determine if higher levels of
prescription misuse was associated with higher levels of alexithymia, higher emotional
ambivalence, lower emotional approach coping, and more experience/impact of trauma,
beyond

traditional,

pain,

and

cognitive/social factors.

Prescription

misuse

is

characterized by aberrant medication related behaviors that suggest risky decisions or
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behaviors which may not meet the level of DSM-IV-TR symptomology. Prescription
opioid misuse was operationalized as the total score on the Prescription Drug Use
Questionnaire (PDUQ), which consisted of items such as requesting refills before a
prescription should have run out, reporting that family members are worried about their
prescription use, feeling as though their doctor does not give them enough medication,
etc. Symptoms of abuse and dependence are characterized as meeting clinical criteria
for problematic use. Total number of symptoms of abuse and dependence on
prescription opioids was operationalized as the number of abuse and dependence
symptoms reported on the SCID, which assesses DSM-IV-TR substance use disorder
symptoms. Abuse is characterized by a single DSM-IV-TR abuse symptom during the
past 12 months (abuse diagnosis is excluded if dependence criteria are met at any point
in one’s lifetime) and dependence is characterized by any 3 DSM-IV-TR dependence
symptoms occurring during the same 12-month period.
These outcomes were zero-order correlated with each predictor measure, and to
reduce the number of variables entered into the model, only those variables that were
marginally or significantly correlated with prescription misuse and symptoms of abuse
and dependence were entered into the regression.
A hierarchical regression by blocks was conducted to determine whether emotion
regulation measures increase predictive validity, in the following order (including only
those variables from each block which were significantly zero-order correlated):
assessment method group (as a control variable) demographic information/use history,
pain variables, social/personality variables, and emotional variables. Personal history of
substance use problems was excluded from all regressions because it was determined
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that this characteristic: a) has strong research evidence that it is predictive of misuse
and this study sought to determine additional factors that might predict for an individual
who has never had misuse problems; b) it was determined that this characteristic likely
inherently included the primary outcome of interest in that participants would respond
positively to having a history of substance use problems if they believed they currently
had a problem with their prescriptions.
Additionally, hierarchical regressions were repeated using the same selected
variables for demographic/traditional factors, pain, and social/personality, with each
individual emotional variable (Toronto Alexithymia Scale, Ambivalence Over Emotional
Expression, Emotional Approach Coping, and Impact of Events Scale). The purpose of
these additional analyses was to explore the role of each emotional factor without
controlling for the role of the other emotional factors.
Personal history of substance use problems was excluded from the regression
analyses for three reasons. First, the primary goal of the current study was to add to the
theoretical understanding of what personal characteristics may increase the risk of
engaging in prescription opioid misuse. Although personal history of substance use is
likely pragmatically useful in identifying who should not be prescribed opioids, it does
not add to the theoretical understanding of what personal characteristics make
someone at higher risk of developing prescription misuse problems. There are
hypothetically also instances in which participants may not have abused drugs prior to
being prescribed an opioid, but understanding the personal characteristics that may put
them at higher risk and engaging in prevention efforts may be valuable. There may also
be instances in which patients are unlikely to admit to prior substance use history and
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having an understanding of the other factors that may put those individuals in a higher
risk category is essential. Second, there were measurement issues in the current study
which made it difficult to determine whether prescription opioid misuse was treated as
separate from prior substance use history in participants’ responses. Unfortunately, the
wording of the question left open the possibility that some participants may have
included ongoing prescription misuse in their answer of "yes" meaning that we would be
controlling for the outcome we were trying to predict. Third, despite the strong prior
evidence that prior history of substance use is related to prescription misuse, it only
provides evidence that a past behavior predicts similar future behavior and for some
participants it actually was opioids that they reported having problems with at some
previous time and thus those participants were already experiencing problems
controlling their behavior related to the same drug they are being medically provided. Of
note, regressions were run controlling for personal history of substance use and it was
found that none of the pain, social/cognitive, or emotional variables were significant,
although emotional ambivalence had a marginal relationship with total number of
prescription opioid abuse and dependence symptoms.
Hypothesis 2. Hierarchical and logistic regressions were run to determine if
higher levels of alcohol/illicit drug use were associated with higher levels of alexithymia,
lower levels of emotional approach coping, and more experience/impact of trauma,
beyond traditional, pain, and cognitive/social factors. Alcohol use was operationalized
as the number of days out of the past 30 that participants reported drinking. Alcohol use
was zero-order correlated with each predictor measure, and to reduce the number of
variables entered into the model, only those variables that were marginally or
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significantly correlated were included in the regression. As with prescription misuse,
personal history of substance use was excluded from the regression model. A
hierarchical regression by blocks was conducted to determine whether emotion
regulation measures increase predictive validity, in the following order (including only
those variables from each block which were significantly zero-order correlated):
assessment method group (as a control variable), demographic information/use history,
pain variables, social/personality variables, and emotional variables. Personal history of
substance use problems was excluded from all regression models.
Because fewer participants reported cannabis use than alcohol use, participants
were dichotomously coded as users (1 or more days of use in the past 30 days) or nonusers (no use of cannabis in the past 30 days; see Table 5). Variables entered into the
model were selected in the same way as days of alcohol use. A logistic regression was
run to predict cannabis users and non-users. It should be noted that all other drug
categories had too few active users to run a regression.
Additionally, hierarchical and logistic regressions were repeated using the same
selected variables for demographic/traditional factors, pain, and social/personality, with
each individual emotional variable (Toronto Alexithymia Scale, Ambivalence Over
Emotional Expression, Emotional Approach Coping, and Impact of Events Scale). The
purpose of these additional analyses was to explore the role of each emotional factor
without controlling for the role of the other emotional factors.
Hypothesis 3. To determine if the three different conditions led to differing
amounts of disclosure of aberrant use of prescription drugs, a 3-group ANOVA followed
by Scheffe post-hoc tests was used to examine differences among disclosure methods
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on the number of symptoms reported on the PDUQ, LSC-R, and number of symptoms
of abuse/dependence on prescription opioids, alcohol, and all other drugs.
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CHAPTER 3
RESULTS
Detailed Description of Pain and Substance History
Pain condition. Most participants (n = 67; 67%) reported that a specific event
such as a car accident, work related accident, or a fall led to at least one of their selfreported pain conditions. The most common diagnoses were as follows: 70 with chronic
back pain (70%), 25 with knee and leg pain (25%), 20 with arthritis (20%), 14 with
degenerative disorders and neuropathy (14%),13 with head and neck pain (13%), 8 with
abdominal pain (8%), 6 with fibromyalgia (6%), 6 with shoulder injuries (6%), and 5 with
pinched nerves (5%). Note that the total is over 100 because many participants reported
more than one pain condition. Participants had been experiencing their pain symptoms
for an average of 12.93 years (SD = 11.09)
Prescription use. The most common prescription medications were Vicodin (69
participants; 69%), Tylenol 3 and Tylenol 4 (11 participants; 11%), and Oral Morphine
(11 participants). Other medications included Dilaudid, Darvocet, Loritab, Methadone,
Norco, and Oxycodone. Nearly half of the participants were prescribed more than one
opioid pain medication (e.g., methadone and a shorter acting medication, oral pain
prescription and a Fentanyl patch, etc.). Regarding the pain relief that participants
reported experiencing from their medications, 79.2% of patients rated the pain relief as
“5” or more on a scale of 1 to 10 (“1 no pain relief” to “10 complete pain relief”), but only
10 participants reported that their medication was capable of removing their pain
completely. The majority of the participants reported that they take their prescription
daily (n = 83; 83%). A quarter (n = 25; 25%) of the participants had been taking their
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current prescription for one year or less, and only 26 participants had been taking their
current prescription for more than 5 years.
Pain management. Participants reported a variety of treatments other than
medication since their diagnosis: 82 participants reported trying physical therapy, 11
reported engaging in psychological interventions for pain including individual treatment
sessions and relaxation training, 10 reported having surgeries or nerve blocks, and 6
reported getting massages or going to a chiropractor.
Psychiatric and substance abuse history. Over half of the participants
reported that they had been in psychiatric treatment at some point during their lives (n =
55; outpatient therapy, inpatient treatment, etc.), and 53 participants reported that they
had been prescribed a psychiatric medication (53%). Regarding family history, 35
participants reported that one or more of their immediate family members had received
psychiatric treatment (35%).
Nearly a quarter of the participants reported that they had previously been in a
substance abuse treatment program (n = 23). Nearly half of the participants reported
that they believed they had a problem with drugs at some point in their life (n = 41) and
21 participants reported a problem with alcohol. The most common drugs that
participants reported having a past problem with were: cocaine (n = 11), heroin (n = 12),
and marijuana (n = 11; see Table 3 for rates of past and current symptoms of abuse and
dependence on alcohol and other drugs). Past research has shown that having a parent
with a substance use problem can lead to a greater risk of substance use problems in
their offspring. Many participants in this sample reported familial problems with alcohol
or drugs: 11% father had problems with drugs (n = 11), 39% father had problems with
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alcohol (n = 39), 12% mothers had problems with drugs (n = 12), 21% mother had
problems with alcohol (n = 21), and 36% had a family member who had been in
substance use treatment (n = 36).
For all predictor and outcome measures used, see Table 1 and 2 below for mean
and standard deviation values.
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Table 1

Means and Standard Deviations of Predictor Measures

Basic
Age
BSI.GSI
Pain
BPI
PCS-TOT
PASS-TOT
Social/Cognitive
SPS-TOT
EXPECT
TIPI-EXTRAV
TIPI-OPEN
TIPI-AGREE
TIPI-CONSC
TIPI-STABLE
Emotional
TAS-TOT
AEQ-TOT
IES-TOT
EAC-TOT

Mean

Standard
Deviation

47.57
1.25

11.57
0.86

6.55
30.87
53.67

1.72
13.06
23.99

3.03
2.68
4.14
5.07
5.16
5.51
4.61

0.48
0.86
1.62
1.36
1.33
1.39
1.52

52.29
3.02
5.46
2.61

13.30
0.95
3.22
0.73

Note: Definitions of variable names – BSI.GSI (Global Severity Index of the Brief
Symptom Inventory), BPI (Brief Pain Inventory, Severity Score), PCS-TOT (Total Score
of the Pain Catastrophizing Scale), PASS-TOT (Total Score of the Pain Anxiety
Symptom Scale), SPS-TOT (Total Score of the Social Provisions Scale), EXPECT
(Belief that more medication is needed than other individuals from the Medication
Beliefs Scale), TIPI-EXTRAV (Extraversion), TIPI-OPEN (Openness), TIPI-AGREE
(Agreeableness), TIPI-CONSC (Conscientiousness), TIPI-STABLE (Emotional stability
which is the inverse of neuroticism), TAS-TOT (Total Score of the Toronto Alexithymia
Scale), AEQ-TOT (Total Score of the Ambivalence Over Emotional Expression Scale),
IES-TOT (Total Score of the Impact of Events Scale), and EAC-TOT (Total Score of the
Emotional Approach Coping Scale). Additional measures referred to throughout the
study are: AODHx (personal history of alcohol or drug problems), ParentHx (parent
history of alcohol or drug treatment)
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Table 2

Means and standard deviations M (SD) of continuous outcome measures

and numbers and percentage n (%) of dichotomous variables

Prescription Opioid
Outcomes
Prescription Drug
Use Questionnaire
Symptoms of
prescription abuse
Symptoms of
prescription
dependence
Total number of
abuse and
dependence
symptoms
# of participants
reporting any
abuse or dependence
symptoms
Alcohol Outcome
Days of alcohol use
out of past 30 days
Alcohol user (any
use in the past 30
days)
Cannabis Outcome
Cannabis user (any
use in the past 30
days)
Trauma Outcomes
Life Stressors
Checklist # of
Events
Life Stressors
Checklist average
level of distress

Mean/#

Standard
Deviation/
%

9.46

4.18

0.23

0.57

1.36

1.44

1.59

1.74

67

67%

3.17

6.94

41

41%

25

25%

10.97

5.37

2.64

0.99

Note: Categorical values which are displayed as n and percentage are italicized;
continuous variables displayed as mean and standard deviations are not italicized.
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Hypothesis 1
Hypothesis 1 tested whether stress/emotional factors could predict prescription
misuse (as measured by the total score of the Prescription Drug Use Questionnaire)
and symptoms of prescription opioid abuse and dependence (as quantified by both
number of DSM-IV-TR symptoms of abuse and dependence and the qualitative
diagnosis of dependence) beyond the more routinely assessed predictive factors
(demographic,

pain-related,

and

cognitive/social).

Assessment

method

group

assignment was controlled for by entering it into the first block of all regression
analyses.
Overview of Hypothesis 1. Zero-order correlations were run to first understand
the relationship of all predictor measures to the Prescription Drug Use Questionnaire
and prescription opioid abuse and dependence symptoms. Second, based upon the
significant zero-order correlations, partial correlations were run controlling for any
significant traditional and/or pain predictors to determine if the correlations between
Prescription Drug Use Questionnaire and the number of abuse and dependence
symptoms on current prescription opioid medication to emotional variables remained
once the effect of demographic and pain variables were parceled out. Partial
correlations were run controlling for a) any significant traditional variables and/or pain
variables; b) controlling for each of those traditional factors individually. Third, to reduce
the number of variables entered into the regression models, regressions were run using
only those variables that had at least a marginally significant relationship with the
Prescription Drug Use Questionnaire total score, the number of prescription opioid
symptoms of abuse and dependence, and the categorical definition of being dependent
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on their prescription opioid. An exception to this process was that all emotional variables
(Toronto Alexitymia Scale, Ambivalence Over Emotional Expression Scale, Impact of
Events Scale, and Emotional Approach Coping Scale) were included in the models
regardless of their zero-order correlations with the outcome because these variables
were of primary interest. Hierarchical regressions were run for the total score of the
Prescription Drug Use Questionnaire and the total number of abuse and dependence
symptoms and a logistic regression was run for diagnosis of dependence. Finally,
regressions were repeated individually for each emotional predictor so that the effect of
each emotional variable could be examined without controlling for the other emotional
variables.
Predicting scores on the Prescription Drug Use Questionnaire. Participants
reported a mean score of 9.46 (SD = 4.18) on the Prescription Drug Use Questionnaire
total score. Only 7 participants reported that they had used their prescription medication
to “feel high” (7%). Forty-nine (49%) of participants had scores at or higher than the cutoff (i.e., a score of 10 or higher) established for probable problematic use of prescription
medication (Compton et al., 2008).
Zero-order correlations of predictors with the Prescription Drug Use
Questionnaire. Correlations between the predictors and total score of the Prescription
Drug Use Questionnaire can be seen in Table 6. Personal history of alcohol or drug use
problems, parental history of alcohol or drug use treatment, increased symptoms as
measured by the Global Severity Index of the Brief Symptom Inventory, higher total
scores on the Toronto Alexithymia Scale, and higher total scores on the Ambivalence
Over Emotional Expression Scale were significantly correlated with higher total scores
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on the Prescription Drug Use Questionnaire. Additionally, there was a trend suggesting
that lower levels of extraversion were related to higher reports of prescription misuse. It
is important to note that none of the pain variables were significantly correlated with the
Prescription Drug Use Questionnaire (see Table 6).
Partial correlations of predictors with the Prescription Drug Use
Questionnaire. Variables that were significantly zero-order correlated with prescription
misuse (parental history of alcohol or drug use treatment, Global Severity Index of the
Brief Symptom Inventory/psychiatric symptoms) were entered as control variables in
partial correlations of all social/cognitive and emotional factors with the Prescription
Drug Use Questionnaire (see Table 7). None of the social/cognitive or emotional
variables remained significant after controlling for these variables all at once or when
parental history of alcohol or drug use treatment and Global Severity Index of the Brief
Symptom Inventory were controlled for separately.
Hierarchical regression predicting the Prescription Drug Use Questionnaire
with all emotional variables. A hierarchical regression model composed of the
following blocks of variables was conducted: control (assessment method group),
traditional factors (parental history of alcohol or drug use treatment and psychiatric
symptoms), social/cognitive factors (extraversion), and emotional factors (because
these variables were of specific interest, all were included in the model). The regression
was significantly predictive of the Prescription Drug Use Questionnaire total score, (R2 =
.24, F(8, 91) = 3.65, p < .01; see Table 8). However, emotional variables did not explain
a significant increase in variance from the control, traditional, and social/cognitive
factors alone (p = .34). Having a family history of substance use problems significantly
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predicted increased prescription misuse as measured by the Prescription Drug Use
Questionnaire, β = .35, t(91) = 3.73, p < .001. Additionally, there was a trend for higher
total scores on the Ambivalence Over Emotional Expression Scale as predictive of
increased prescription misuse, β = .23, t(91) = 1.79, p = .08.
Hierarchical regression predicting the Prescription Drug Use Questionnaire
with each emotional variable independently. A hierarchical regression model
composed of the following blocks of variables was conducted: control (assessment
method group), traditional factors (parental history of alcohol or drug use treatment and
psychiatric symptoms), social/cognitive (extraversion) and each emotional factor
individually.
Toronto Alexithymia Scale total score. The regression was significantly predictive
of the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) = 5.05, p <
.01; see Table 8). However, alexithymia did not explain a significant increase in
variance from the control, traditional, and social/cognitive factors alone (p = .37), even
without controlling for other emotional characteristics.
Ambivalence Over Emotional Expression total score. The regression was
significantly predictive of the Prescription Drug Use Questionnaire total score, (R2 = .24,
F(5, 94) = 5.84, p < .01; see Table 8), and the addition Ambivalence Over Emotional
Expression explained a significant increase in variance from the control, traditional, and
social/cognitive factors alone (∆R2 = .03, p < .05). Higher total scores on the
Ambivalence Over Emotional Expression Scale were related to increased scores on the
Prescription Drug Use Questionnaire, β = .22, t(94) = 1.99, p < .05. Thus, once
removing the other emotional variables from the regression, higher levels of
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Ambivalence Over Emotional Expression became a significant predictor for prescription
misuse.
Impact of Events Scale total score. The regression was significantly predictive of
the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) = 4.89, p < .01;
see Table 8). However, the Impact of Events Scale did not explain a significant increase
in variance from the control, traditional, and social/cognitive factors alone (p = .66), even
without controlling for other emotional variables.
Emotional Approach Coping total score. The regression was significantly
predictive of the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) =
4.97, p < .01; see Table 8). However, the Emotional Approach Coping total score did
not explain a significant increase in variance from the control, traditional, and
social/cognitive factors alone (p = .47), even without controlling for other emotional
characteristics.
In summary, for prescription misuse as measured by the Prescription Drug Use
Questionnaire, Hypothesis 1 was only partially supported. Higher scores on the
Ambivalence Over Emotional Expression scale were significantly predictive of increased
prescription misuse; however, no relationship existed between alexithymia, trauma, or
the Emotional Approach Coping Scale and prescription misuse after controlling for
assessment method group assignment, family history of substance use treatment,
psychiatric symptoms and extraversion.
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Table 6

Correlations of predictors and prescription drug misuse and symptoms of

abuse and dependence
Prescription
Drug Use
Questionnaire
Basic
Age
Sex
AODHx
ParentHx
BSI.GSI
Pain
BPI
PCS-TOT
PASS-TOT
Social/Cognitive
SPS-TOT
EXPECT
TIPI-EXTRAV
TIPI-OPEN
TIPI-AGREE
TIPI-CONSC
TIPI-STABLE (N)
Emotional
TAS-TOT
AEQ-TOT
IES-TOT
EAC-TOT

Abuse and
Dependence
Symptoms

Current
Dependence on
Prescription
(Y/N)

.04
-.08
.47**
.35**
.26**

.18
-.05
.27**
.21*
.05

.11
-.08
.27**
.19†
.09

-.01
.12
.17

.08
.14
.16

.15
.13
.21*

-.10
.15
-.17†
-.13
-.14
-.16
-.03

-.02
-.01
.02
-.17†
-.15
-.09
-.21*

-.08
-.01
-.07
-.06
-.03
-.10
-.20*

.21*
.31**
.16
-.12

.12
.29**
.14
-.01

.18†
.18†
.21*
.04

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.
Current dependence was coded as 1 = current dependence diagnosis; 0 = no current
dependence diagnosis.
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Table 7
Partial correlations of predictors and prescription drug misuse and
symptoms of abuse and dependence after controlling for traditional and pain variables
significantly correlated with each outcome measure*
Prescription
Drug Use
Questionnaire

Abuse and
Dependence
Symptoms

Current
Dependence on
Prescription
(Y/N)

Social/Cognitive
SPS-TOT
.18
-.03
-.02
EXPECT
.11
-.01
-.04
TIPI-EXTRAV
-.24
.01
-.06
TIPI-OPEN
.29
-.21**
-.04
TIPI-AGREE
-.09
-.16
-.03
TIPI-CONSC
.08
-.08
-.04
TIPI-STABLE (N)
.13
-.19
-.12
Emotional
TAS-TOT
-.14
.11
.07
AEQ-TOT
-.05
.27**
.06
IES-TOT
-.17
.13
.11
EAC-TOT
-.05
-.01
.04
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
See Table 1 for variable definitions. Current dependence was coded as 1 = current
dependence diagnosis; 0 = no current dependence diagnosis. See Table 1 for variable
definitions. *Partials for the Prescription Drug Use Questionnaire were controlled for by
family history of alcohol or drug treatment and psychiatric symptoms. Abuse and
dependence symptoms were controlled for by family history of drug or alcohol treatment
only. Current dependence on prescription opioids was controlled for by family history of
drug or alcohol treatment and the Pain Anxiety Symptom Scale.
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Table 8
Predictors of prescription misuse (total score of the Prescription Drug Use
Questionnaire)
All Emotional
Variables
2
∆R
β
Step 1
Group
(control)

.01

Step 2 (Basic)
ParentHx
BSI.GSI

.17**

Step 3 (Cog)
TIPI-Extrav

.03

Step 5 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

.03

Each Emotional
Variable Entered
Separately
2
∆R
β

-.14

.35**
.04
†

-.15

-.03
†
.23
.01
-.09

.01
†
.03
.01
.01

.11
.22*
.05
-.07

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.
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Predicting symptoms of prescription opioid abuse and dependence.
Regarding DSM-IV-TR criteria for abuse and dependence symptoms for their current
prescription medications, the average number of symptoms was 1.59 (SD = 1.74), with
the most common symptoms reported being: often using more than planned/prescribed
(dependence symptom), repeated unsuccessful attempts to stop using (dependence
symptom), withdrawal symptoms (dependence symptom), tolerance to the effects
(dependence symptom), and feeling intoxicated while doing an important activity (abuse
symptom; see Table 9 for number of participants reporting each symptom of abuse and
dependence).
Zero-order correlations of predictors with number of prescription opioid
abuse and dependence symptoms. Personal history of alcohol or drug use problems,
parental history of alcohol or drug use treatment, lower scores on emotional stability
(low scores on emotional stability suggest higher levels of neuroticism) as measured by
the Ten Item Personality Inventory, and higher total scores on the Ambivalence Over
Emotional Expression Scale were significantly correlated with total number of
prescription opioid abuse and dependence symptoms. There was a trend for lower
levels of openness to correlate with an increased number of symptoms. None of the
pain variables were significantly correlated with the number of abuse and dependence
symptoms (see Table 6).
Partial correlations of predictors with the symptoms of prescription opioid
abuse and dependence. After determining the traditional (parental history of alcohol or
drug use treatment) and pain factors (none) that were significantly zero-order correlated
with the total number of symptoms, that variable was entered as a control variable in a
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partial correlation of the total number of current abuse and dependence symptoms on
prescription opioids and all social/cognitive and emotional variables. After controlling for
family history, as predicted, higher scores on the Ambivalence over Emotional
Expression Scale were correlated with more symptoms of abuse and dependence on
prescription opioid medications. Additionally, lower levels of openness were also
correlated with higher numbers of symptoms (see Table 7).
Hierarchical regression predicting the total number of symptoms of
prescription opioid abuse and dependence with all emotional variables. A
hierarchical regression model composed of the following blocks of variables was
conducted: control (assessment method group), traditional factors (parental history of
alcohol or drug use treatment), social/cognitive factors (emotional stability and
openness), and emotional factors (because these variables were of specific interest, all
were included in the model). The regression was significantly predictive of total number
of symptoms of prescription opioid abuse and dependence, (R2 = .24, F(8, 91) = 3.68, p
< .01; see Table 10). However, the emotional variables did not explain a significant
increase in variance from the control, traditional, and social/cognitive factors alone (p =
.39). Having a family history of substance use problems was significantly predictive of a
higher number of abuse and dependence symptoms, β = .26, t(91) = 2.68, p < .01.
Additionally, there was a trend for higher total scores on the Ambivalence Over
Emotional Expression Scale as predictive of increased prescription misuse, β = .26,
t(91) = 1.97, p = .05. Thus, when all emotional variables are controlled for in the
regression model, the only variable that has a marginal relationship with the number of
abuse and dependence symptoms is ambivalence.
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Hierarchical regression predicting the total number of prescription opioid
abuse and dependence symptoms with each emotional variable independently. A
hierarchical regression model composed of the following blocks of variables was
conducted: control (assessment method group), traditional factors (parental history of
alcohol or drug use treatment), social/cognitive factors (emotional stability and
openness), and each emotional factor individually.
Toronto Alexithymia Scale total score. The regression was significantly predictive
of total number of prescription abuse and dependence symptoms, (R2 = .21, F(5, 94) =
5.02, p < .01; see Table 10). However, it was found that the alexithymia did not explain
a significant increase in variance from the control, traditional, and social/cognitive
factors (p = .71), even without controlling for other emotional characteristics.
Ambivalence Over Emotional Expression total score. The regression was
significantly predictive of total number of prescription abuse and dependence
symptoms, (R2 = .24, F(5, 94) = 5.79, p < .01; see Table 10) and the addition of the
emotional variable block explained a marginal increase in variance from the control,
traditional, and social/cognitive factors alone (∆R2 = .05, p = .08). Higher total scores on
the Ambivalence Over Emotional Expression Scale were marginally related to higher
total number of abuse and dependence symptoms, β = .18, t(94) = 1.79, p = .08. Thus,
once removing the other emotional variables from the regression, higher scores on the
Ambivalence Over Emotional Expression Scale became a marginal predictor for total
number of abuse and dependence symptoms.
Impact of Events Scale total score. The regression was significantly predictive of
total number of prescription abuse and dependence symptoms, (R2 = .21, F(5, 94) =
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5.01, p < .01; see Table 10). However, trauma symptoms did not explain a significant
increase in variance from the control, traditional, and social/cognitive factors (p = .75),
even without controlling for other emotional characteristics within the model.
Emotional Approach Coping total score. The regression was significantly
predictive of total number of prescription abuse and dependence symptoms, (R2 = .21,
F(5, 94) = 5.01, p < .01; see Table 10). However, emotional approach coping did not
explain a significant increase in variance from the control, traditional, and
social/cognitive factors (p = .71), even in the absence of controlling for the other
emotional variables.
In summary, regarding the continuous measure of number of DSM-IV-TR abuse
and dependence symptoms for prescription opioids, Hypothesis 1 was only partially
supported. Higher scores on the Ambivalence Over Emotional Expression scale were
marginally predictive of total number of prescription abuse and dependence symptoms;
however, no relationship existed between alexithymia, trauma, or emotional approach
coping and the total number of prescription opioid abuse and dependence symptoms
after controlling for assessment method assignment, family history of substance abuse
treatment, openness to experience, and emotional stability.
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Table 9

Symptoms of abuse and dependence reported for prescription opioids
Number of
Participants

Percentage of
Participants

Abuse
Intoxicated during
12
12%
important
activities
Using during risky
6
6%
activities (e.g.,
driving)
Legal problems
3
3%
related to use
Social or
5
5%
interpersonal
problems
Dependence
Tolerance
12
12%
Withdrawal
31
31%
Using more than
20
20%
planned
Unsuccessful desire
33
33%
to quit
Great deal of time
4
4%
using
Interference with
8
8%
activities
Continued use
10
10%
despite harm
Note: Abuse symptoms are based on report of recurrence of each item, not a single
incident; diagnosis of current abuse is determined by the occurrence of any one of the
abuse symptoms during the past 12 month period without ever meeting criteria for
dependence; diagnosis of current dependence is determined by the occurrence of any 3
of the dependence symptoms during the past 12 months

76
Table 10

Predictors of total number of current prescription opioid symptoms of

abuse and dependence
All Emotional
Variables
2
∆R
β
Step 1
Group
(control)

.08**

Step 2 (Basic)
ParentHx

.07**

Step 3 (Cog)
TIPI-Open
TIPI-Stable

.05*

Step 4 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

.04

Emotional
Variables Entered
Separately
2
∆R
β

-.32**

.26*

-.14
-.09

-.12
†
.26
-.03
-.05

.01
.01
†
.03
.01
.01

.04
†
.18
.03
-.04

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.

77
Predicting diagnosis of opioid dependence. Eight participants met criteria for
current abuse of their prescription medication using DSM-IV-TR criteria and an
additional 18 participants met criteria for current dependence of their prescription
medication (see Table 3).
Zero-order correlations of predictors with diagnosis of opioid dependence.
Personal history of alcohol or drug problems, parental history of alcohol or drug use
treatment, higher total score on the Pain Anxiety Symptom Scale, lower levels of
emotional stability (indicative of neuroticism), and higher levels of trauma symptoms (as
measured by the total score from the Impact of Events Scale) were significantly
correlated with increased probability of meeting diagnostic criteria for current
prescription opioid dependence. Additionally, higher scores on the Toronto Alexithymia
Scale and the Ambivalence Over Emotional Expression Scales were marginally
predictive of meeting diagnostic criteria for prescription opioid dependence (see Table
6).
Partial correlations of predictors with diagnosis of opioid dependence.
Parental history of alcohol or drug use treatment and Pain Anxiety Symptom Scale total
score were entered as control variables in a partial correlation of all social/cognitive and
emotional variables and whether or not each participant met criteria for prescription
opioid dependence. None of the social/cognitive or emotional variables remained
significant after controlling for these variables (see Table 7).
Logistic regression predicting diagnosis of opioid dependence with all
emotional variables. A logistic regression model composed of the following blocks of
variables was conducted: control (assessment method group), traditional factors
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(parental history of alcohol or drug use treatment), pain (Pain Anxiety Symptoms Scale),
social/cognitive factors (emotional stability), and emotional factors (because these
variables were of specific interest, all were included in the model). The full model
containing all predictors was statistically significant, Χ2 (7, N = 100) = 17.60, p = .02,
indicating that the model was able to distinguish between participants who reported
symptoms consistent with a diagnosis of prescription opioid dependence and those who
did not (see Table 11). The model as a whole correctly classified 80.0% of cases who
were opioid dependent. Only one of the independent variables made a unique
statistically significant contribution to the model, family history of alcohol or drug
treatment, with an odds ratio of 3.82, which indicated that participants who had a family
history of drug treatment were almost 4 times more likely to have diagnosis of
prescription opioid dependence than participants without a family history.
Logistic regression predicting diagnosis of opioid dependence with each
emotional variable independently. A logistic regression model composed of the
following blocks of variables was conducted: control (assessment method group),
traditional factors (parental history of alcohol or drug use treatment), social/cognitive
factors (emotional stability and openness), and each emotional factor individually.
Consistent with the results of the full logistic model, family history of drug or alcohol
treatment remained the only significant predictor of diagnosis of prescription opioid
dependence, with participants who had a family history of drug treatment having been
nearly 4 times more likely to report symptoms consistent with a diagnosis of prescription
opioid dependence. See Table 11 for all values.
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In summary, regarding the dichotomous measure of whether or not participants
reported symptoms consistent with a diagnosis of dependence on prescription opioids,
Hypothesis 1 was not supported. Only family history of drug or alcohol treatment was
predictive of a diagnosis of prescription opioid dependence. None of the emotional
variables explained unique variance in the model after controlling for assessment
method assignment, family history of drug or alcohol treatment, Pain Anxiety Symptom
Scale total score, and emotional stability.

80
Table 11

Predictors of current diagnosis of prescription opioid dependence
2

Step 1
Group
(control)
Step 2 (Basic)
ParentHx
Step 3 (Pain)
PASS-Tot
Step 4 (Cog)
TIPI-Stability
Step 5 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

All Emotional
Variables
B(SE B)

e

-1.02 (0.42)*

0.36

1.34 (0.62)*

3.82

0.01 (0.02)

1.01

-0.26 (0.23)

0.77

0.01 (0.03)
-0.15 (0.45)
0.11 (0.14)
-0.02 (0.44)

1.01
0.86
1.11
0.98

B

Χ

2

17.60*

Emotional Variables
Entered Separately
B
B(SE B)
e

Χ Values for Full
Models of
Emotional
Variables Entered
Separately
2
Χ

0.02 (0.03)
0.05 (0.38)
0.11 (0.12)
-0.01 (0.41)

16.90**
16.63**
17.40**
16.61*

1.02
1.06
1.11
1.00

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables
determined by the Wald’s test. See Table 1 for variable definitions.
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Hypothesis 2
Hypothesis 2 tested the hypothesis that stress/emotional factors could predict
alcohol and other drug use beyond the more routinely assessed predictive factors
(demographic, pain-related, cognitive/social, and stress/emotional factors). The two
outcome categories were alcohol and cannabis as they were the most frequently
reported drugs of abuse. For alcohol, both a categorical value of current user versus not
a current user (any days of use during the past month) and a continuous measure of the
number of days of use during the last month (to assess degree of current use) were
evaluated. Because there were fewer participants reporting use of cannabis, only the
categorical variable of “user” versus “non-user” was evaluated in a logistic regression.
Use was operationalized as either “users” who had used 1 or more days of use in the
past 30 days or “non-users” who reported no use in the past 30 days for both alcohol
and cannabis.
Predicting Days of Alcohol Use. Participants reported a mean of 3.26 days (SD
= 7.02) of drinking alcohol out of the past 30 days. Regarding DSM-IV-TR criteria for
abuse and dependence symptoms for alcohol, the average number of symptoms was
0.73 (SD = 2.01). Twenty-one participants met criteria for abuse of alcohol using DSMIV-TR criteria at any time in their lives (2 participants met criteria at the time of
participation), and 24 participants met criteria for dependence on alcohol at any time in
their lives (12 participants met criteria at the time of participation). It is important to note
that a diagnosis of alcohol dependence at any time in a participant’s life excludes a
diagnosis of abuse, thus more than 21 participants reported symptoms of abuse but had
also reported symptoms consistent with a diagnosis of dependence and were excluded
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from the abuse category. Correlations between the predictors and days of alcohol use
out of the past 30 days and the categorical variable of current alcohol user versus nonuser are presented in Table 12.
Zero-order correlations of predictors with days of alcohol use during the
past 30 days. Personal history of alcohol or drug use problems, parental history of
alcohol or drug use treatment, higher levels of psychiatric symptoms (as measured by
the Brief Symptom Inventory Global Severity Index), higher scores on the Pain
Catastrophizing Scale, lower scores on emotional stability (low scores on emotional
stability suggest higher levels of neuroticism) as measured by the Ten Item Personality
Inventory, lower scores on agreeableness (as measured by the Ten Item Personality
Inventory), and higher total scores on the Ambivalence Over Emotional Expression
Scale (see Table 12) were correlated with total days of alcohol use out of the past 30.
Partial correlations of predictors with days of alcohol use during the past
30 days. Parental history of alcohol or drug use treatment, higher levels of psychiatric
symptoms, and total score on the Pain Catastrophizing Scale were entered as control
variables in a partial correlation of all social/cognitive and emotional variables with the
total days drinking alcohol during the past month. Lower scores on agreeableness
remained significantly correlated with more days of drinking alcohol during the past 30
days even after controlling for parental history of alcohol or drug use treatment,
psychiatric symptoms, and the Pain Catastrophizing Scale (see Table 13).
Hierarchical regression predicting the days of alcohol use during the past
30 days with all emotional variables. A hierarchical regression model composed of
the following blocks of variables was conducted: control (assessment method group),
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traditional (parental history of alcohol or drug use treatment, higher levels of psychiatric
symptoms), pain (Pain Catastrophizing Scale), social/cognitive factors (extraversion and
agreeableness), and emotional factors (because these variables were of specific
interest, all were included in the model).
The regression was significantly predictive of total number days of alcohol use
out of the past 30 days, (R2 = .24, F(10, 89) = 2.84, p < .01; see Table 14). As
hypothesized, the emotional variables explained a significant increase in variance (∆R2
= .09 p= .04). Higher scores on the Ambivalence Over Emotional Expression Scale
were significantly predictive of more days of alcohol use, β = .29, t(89) = 2.09, p =.04,
even after controlling for all other traditional, pain, social/cognitive, and emotional
factors. Lower scores on the Toronto Alexithymia Scale were significantly associated
with more days of alcohol use out of the past 30 (β = -.40, t(89) = -2.72, p < .01),
however, this was not in the direction hypothesized. Higher scores on the Pain
Catastrophizing Scale (β = .29, t(89) = 2.13, p = .04) was predictive of more days of
alcohol use. Additionally, having a family history of alcohol or drug treatment (β = .19,
t(89) = 1.93, p = .06) and lower levels of agreeableness were marginally predictive of
more days drinking during the past month (β = -.21, t(89) = -1.88, p = .06; see Table
14).
Hierarchical regression predicting days of alcohol use in the past 30 days
with each emotional variable independently. A hierarchical regression model
composed of the following blocks of variables was conducted: control (assessment
method group), traditional (parental history of alcohol or drug use treatment, higher

84
levels of psychiatric symptoms), pain (Pain Catastrophizing Scale), social/cognitive
factors (extraversion and agreeableness), and each emotional factor individually.
Toronto Alexithymia Scale total score. The regression was significantly predictive
of total number days of alcohol use out of the past 30 days, (R2 = .19, F(7, 92) = 3.01, p
< .01; see Table 12). As hypothesized, the emotional variables explained a significant
increase in variance (∆R2 = .04 p= .04), however, it was not in the hypothesized
direction. Lower scores on the Toronto Alexithymia Scale were significantly predictive of
more days of drinking out of the past 30 (β = -.27, t(92) = -1.99, p < .05).
Ambivalence Over Emotional Expression total score. The regression was
significantly predictive of total number days of alcohol use out of the past 30 days, (R2 =
.16, F(7, 92) = 2.45, p = .02; see Table 14). However, emotional ambivalence did not
explain a significant increase in variance from the control, traditional, and
social/cognitive factors alone (p = .41), in the absence of controlling for the other
emotional variables.
Impact of Events Scale total score. The regression was significantly predictive of
total number of days drinking alcohol out of the past 30, (R2 = .18, F(7, 92) = 2.59, p =
.02; see Table 14). However, trauma symptoms did not explain a significant increase in
variance from the control, traditional, and social/cognitive factors alone (p = .17), even
without controlling for other emotional characteristics within the model.
Emotional Approach Coping total score. The regression was significantly
predictive of total number of days drinking alcohol out of the past 30, (R2 = .16, F(7, 92)
= 2.43, p = .03; see Table 14). However, the emotional variable block did not explain a
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significant increase in variance from the control, traditional, and social/cognitive factors
alone (p = .52), even in the absence of controlling for the other emotional variables.
In summary, regarding the continuous measure of number of days drinking
alcohol out of the past 30, Hypothesis 2 was only partially supported. Higher scores on
the Ambivalence Over Emotional Expression scale were predictive of total days drinking
alcohol out of the past 30 in the full model only, in which assessment method
assignment, parent history of substance use treatment, psychiatric symptoms,
medication expectations, agreeableness, emotional stability, and all other emotional
characteristics were controlled. Additionally, there was a significant relationship
between alexithymia and days of alcohol use in the opposite direction than
hypothesized in both the full model and when the other emotional variables were not
controlled for in the model. No relationship existed between total number of days
drinking alcohol out of the past 30 and trauma or the Emotional Approach Coping Scale.
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Table 12

Correlations of predictors and use of alcohol and cannabis during the past

month
Days of alcohol use
last month (0 to 30
scale)
Basic
Age
Sex
AODHx
ParentHx
BSI.GSI
Pain
BPI
PCS-TOT
PASS-TOT
Social/Cognitive
SPS-TOT
EXPECT
TIPI-EXTRAV
TIPI-OPEN
TIPI-AGREE
TIPI-CONSC
TIPI-STABLE
Emotional
TAS-TOT
AEQ-TOT
IES-TOT
EAC-TOT

Alcohol use
during the past
month (Yes/No)

Cannabis use
during the past
month (Yes/No)

-.04
-.06
.27**
.21*
.24**

-.24**
-.11
.12
.01
.26**

-.28**
.04
.01
.01
-.03

.09
.25**
.19

.10
.27**
.17

-.07
.01
.06

-.15
.12
-.05
-.07
-.22*
-.17
-.22*

-.29**
.12
-.11
-.06
†
-.18
-.21*
-.20*

.06
.05
†
.18
.02
.12
.08
-.05

.08
.28**
.08
-.09

.16
.28**
.21*
.04

-.05
-.13
.03
.11

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.
Alcohol use and cannabis use were coded as: 1 = use of alcohol/cannabis during the
past 30 days; 0 = no use of alcohol/cannabis during the past 30 days.
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Table 13

Partial correlations of predictors and use of alcohol and cannabis

controlling for traditional and pain variables that significantly correlated with each
outcome measure*
Days of alcohol
use last month (0
to 30 scale)
Social/Cognitive
SPS-TOT
EXPECT
TIPI-EXTRAV
TIPI-OPEN
TIPI-AGREE
TIPI-CONSC
TIPI-STABLE
Emotional
TAS-TOT
AEQ-TOT
IES-TOT
EAC-TOT

Alcohol use
during the past
month (Yes/No)

Cannabis use
during the past
month (Yes/No)

-.02
.07
.03
.01
-.20*
-.08
-.07

-.17
.07
-.04
.03
-.14
-.08
-.05

.12
.05
.21*
.06
.16
†
.18
.02

-.17
.10
-.13
-.06

-.07
.14
.01
.09

-.11
-.15
-.05
.16

Note: *Correlations for days of alcohol use were controlled by parent history of alcohol
or drug treatment, BSI.GSI, and PCS-TOT. Correlations for alcohol use were controlled
for by age, BSI.GSI, and PCS-TOT. Correlations for cannabis use were controlled for by
age. Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.
Alcohol use and cannabis use were coded as: 1 = use of alcohol/cannabis during the
past 30 days; 0 = no use of alcohol/cannabis during the past 30 days.
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Table 14

Hierarchical regression of days of use of alcohol during the past month
Emotional Variables
Entered Separately
2
∆R
β

All Emotional
Variables
2
∆R
β
Step 1
Group
(control)

.01

Step 2 (Basic)
ParentHx
BSI.GSI

.10**

Step 3 (Pain)
PCS-TOT

.02

Step 3 (Cog)
TIPI-Agree
TIPI-Stable

.04

Step 4 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

.09*

.01

†

.19
.13

.29*

†

-.21
-.04

-.40*
.29*
-.14
-.11

.04*
.01
.01
.01

-.27*
.11
-.15
-.07

Note: † denotes marginal significance (.05 to .10), * denotes significance at the .05 level,
** denotes significance at the .01 level. See Table 1 for variable definitions.
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Predicting alcohol users versus non-users. Forty-one (41%) of participants
were classified as alcohol users during the past month, which was defined as one or
more days drinking alcohol during the past 30 days (see Table 3).
Zero-order correlations of predictors with being a current alcohol user.
Younger age, more psychiatric symptoms (as measured by the Brief Symptom
Inventory Global Severity Index), higher total score on the Pain Catastrophizing Scale,
lower seeking of social support (as measured by the Social Provisions Scale), lower
levels

of

emotional

stability

(indicative

of

neuroticism),

lower

levels

of

conscientiousness, higher scores on the Ambivalence Over Emotional Expression
Scale, and higher levels of trauma symptoms (as measured by the total score from the
Impact of Events Scale) were significantly related to increased probability of being a
current alcohol user. Additionally, lower scores on agreeableness were marginally
predictive being a current alcohol user (see Table 12).
Partial correlations of predictors being a current alcohol user.

Age,

psychiatric symptoms, and total scores on the Pain Catastrophizing Scale were entered
as control variables in a partial correlation of all social/cognitive and emotional variables
and whether or not each participant was an alcohol user. None of the social/cognitive or
emotional variables remained significant after controlling for the traditional/demographic
and pain variables (see Table 13).
Logistic regression predicting being a current alcohol user. A logistic
regression model composed of the following blocks of variables was conducted: control
(assessment method group), traditional factors (age, psychiatric symptoms), pain (Pain
Catastrophizing

Scale),

social/cognitive

factors

(Social

Provisions

Scale,
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agreeableness, conscientiousness, emotional stability), and emotional factors (because
these variables were of specific interest, all were included in the model). The full model
containing all predictors was statistically significant, Χ2 (12, N = 100) = 24.39, p = .02,
indicating that the model was able to distinguish between participants who were current
alcohol users and those who were not. The model as a whole correctly classified 72.0%
of cases as current alcohol users. Only one of the independent variables made a unique
statistically significant contribution to the model: younger age (see Table 15). For each
year a participant was older, the odds of that participant being a current alcohol user
decreased from 1 to 0.95.
Logistic regression predicting being a current alcohol user with each
emotional variable independently. A logistic regression model composed of the
following blocks of variables was conducted: control (assessment method group),
traditional factors (age, psychiatric symptoms), pain (Pain Catastrophizing Scale),
social/cognitive factors (Social Provisions Scale, agreeableness, conscientiousness,
emotional stability), and each emotional factor individually. Consistent with the results of
the full logistic model, younger age remained the only significant predictor of being a
current alcohol user. See Table 15 for all values.
Regarding the dichotomous measure of whether or not participants were current
alcohol users, Hypothesis 2 was not supported. Only younger age significantly predicted
whether or not someone was a current alcohol user. None of the emotional variables
explained unique variance in the model after controlling for assessment method, age,
psychiatric symptoms, total score on the Pain Catastrophizing Scale, agreeableness,
conscientiousness, and emotional stability.
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Table 15

Logistic regression of current alcohol user versus non-user
2

All Emotional
Variables
B
B(SE B)
e
Step 1
Group
(control)
Step 2 (Basic)
Age
BSI.GSI
Step 3 (Pain)
PCS-Tot
Step 4 (Cog)
SPS-Tot
TIPI-AGREE
TIPI-CONSC
TIPI-STABLE
Step 5 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

-0.37 (0.29)

0.69

-0.05 (0.02)*
0.31 (0.43)

0.95
1.36

0.03 (0.03)

1.03

-0.87 (0.60)
-0.23 (0.22)
0.05 (0.22)
0.01 (0.21)

0.42
0.79
1.05
1.01

-0.03 (0.03)
0.49 (0.36)
-0.42 (0.10)
0.31 (0.37)

0.97
1.62
0.96
1.37

Χ

2

24.39**

Emotional Variables
Entered Separately
B
B(SE B)
e

-0.03 (0.02)
0.26 (0.31)
-0.01 (0.10)
0.38 (0.34)

0.98
1.30
1.00
1.46

Χ Values for Full
Models of
Emotional
Variables Entered
Separately
2
Χ

21.68**
21.22**
20.54*
21.80**

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables
determined by the Wald’s test. See Table 1 for variable definitions. Alcohol use was
coded as: 1 = use of alcohol during the past 30 days; 0 = no use of alcohol during the
past 30 days.
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Cannabis use. Participants reported a mean of 4.77 days (SD = 10.29) of using
cannabis out of the past 30 days. Regarding DSM-IV-TR criteria for abuse and
dependence symptoms for cannabis, the average number of current symptoms was
1.02 (SD = 2.06). Thirteen participants met criteria for abuse of cannabis using DSM-IVTR criteria at any time in their lives (5 participants met criteria at the time of
participation) and an additional 22 participants met criteria for dependence on cannabis
at any time in their lives (12 participants met criteria at the time of participation; see
Table 3).
Zero-order correlations of predictors with being a current cannabis user.
Younger age was significantly correlated with an increased probability of being a current
cannabis user. Additionally, higher scores on extraversion were marginally predictive of
being a current cannabis user (see Table 12).
Partial correlations of predictors being a current cannabis user. Age was
entered as a control variable in a partial correlation of all social/cognitive and emotional
variables with whether or not each participant was a cannabis user. Higher levels of
extraversion became significant after controlling for age (see Table 13).
Logistic regression predicting being a current cannabis user. A logistic
regression model composed of the following blocks of variables was conducted: control
(assessment

method

group),

traditional

factor

(age),

social/cognitive

factor

(extraversion), and emotional factors (because these variables were of specific interest,
all were included in the model). The full model containing all predictors was statistically
significant, Χ2 (7, N = 100) = 19.00, p < .01, indicating that the model was able to
distinguish between participants who were current cannabis users and those who were
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not. The model as a whole explained correctly classified 82.0% of cases as current
cannabis users. Only one of the independent variables made a unique statistically
significant contribution to the model: younger age (see Table 16). For each year older a
participant was, his or her odds of being a cannabis user was reduced by 0.93.
Logistic regression predicting being a current cannabis user with each
emotional variable independently. A logistic regression model composed of the
following blocks of variables was conducted: control (assessment method group),
traditional factor (age), social/cognitive factors (extraversion), and each emotional factor
individually. Consistent with the results of the full logistic model, younger age remained
the only significant predictor of being a current cannabis user. See Table 16 for all
values.
In summary, regarding the dichotomous measure of whether or not participants
were current cannabis users, Hypothesis 2 was not supported. None of the emotional
variables explained unique variance in the model after controlling for assessment
method assignment, age, and extraversion.
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Table 16

Logistic regression of current cannabis user versus non-user
2

All Emotional
Variables
B
B(SE B)
e
Step 1
Group
(control)
Step 2 (Basic)
Age
Step 3 (Cog)
TIPI-EXTRV
Step 5 (Emo)
TAS-Tot
AEQ-Tot
IES-Tot
EAC-Tot

-0.55 (0.33)

0.58

-0.08 (0.03)**

0.93

0.31 (0.19)

†

0.03 (0.03)
-0.67 (0.41)
-0.04 (0.11)
0.45 (0.43)

Χ

2

Emotional Variables
Entered Separately
B
B(SE B)
e

Χ Values for Full Models of
Emotional Variables
Entered Separately
2
Χ

-0.01 (0.02)
-0.44 (0.28)
-0.05 (0.08)
0.28 (0.37)

15.12**
17.39**
15.20**
15.39**

1.37
1.03
0.51
0.97
1.57

19.00**

0.99
0.64
0.95
1.32

Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level.
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables
determined by the Wald’s test. See Table 1 for variable definitions. Cannabis use was
coded as: 1 = use of cannabis during the past 30 days; 0 = no use of cannabis during
the past 30 days.
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Hypothesis 3
Hypothesis 3 tested the difference in outcome measures by randomized data
collection method (enhanced interview, standard interview, and written format). Prior to
conducting the analyses, the success of randomization to the assessment method
groups and researcher adherence to assessment method group method was evaluated.
Testing the success of randomization. To determine whether groups were
equivalent prior to randomization to the intervention (i.e., assigned assessment method
group), baseline characteristics of demographics, pain severity, and medication
effectiveness were conducted. The success of the randomization into assessment
method groups was tested using a one-way ANOVA for continuous variables (age, BPI
Total Pain, and Medication Effectiveness) and Chi-Square analyses for categorical
variables (gender, ethnicity). Analyses indicated that there were no baseline differences
among the experimental groups on demographic variables, level of self-reported pain,
or self-reported medication effectiveness in managing pain (see Table 17), which
suggests that groups were equivalent prior to randomization.
Differences based on assessment method group assignment. To explore
group differences on outcome variables a one-way ANOVA with assessment method
group as a fixed factor was run (see Table 2 for all means and standard deviations).
Hypothesis 3 was partially supported. Regarding prescription use, the enhanced group
reported significantly more symptoms of abuse and dependence on their current pain
prescription than the written group, F(2, 97) = 4.49, p = .01. No significant group
differences were found for prescription misuse as measured by the total score of the
Prescription Drug Use Questionnaire. Regarding other substances of abuse, the
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enhanced and standard groups disclosed significantly more current symptoms of
cannabis abuse and dependence (F(2, 97) = 5.55, p < .01) than the written group. No
significant differences among assessment method groups existed for number of alcohol
related symptoms or days of cannabis and alcohol use during the past month.
Regarding trauma, the written group disclosed significantly more distress symptoms of
the Life Stressors Checklist than the standard group, F(2, 97) = 5.70, p < .01.
Additionally, the enhanced group reported marginally more PTSD symptoms than the
written group, F(2,97) = 2.81, p = .07. Assessment method groups did not significantly
differ on number of traumatic life events reported on the Life Stressors Checklist (see
Table 18).
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Table 17

Testing the Success of Randomization

Age (in years)

Enhanced
48.00 (10.54)

Standard
48.97 (12.52)

Written
45.89 (11.71)

Gender (n, %)
Male
Female

16 (48.5%)
17 (51.5%)

15 (46.9%)
17 (53.1%)

16 (45.7%)
19 (54.3%)

Ethnicity (n, %)*
European-American
African-American
Other

5 (15.2%)
28 (84.8%)
0 (0.0%)

3 (10.3%)
26 (89.7%)
0 (0.0%)

3 (9.1%)
27 (81.8%)
3 (9.1%)

BPI Total Score
Medication Effectiveness

6.31 (1.51)
6.69 (1.86)

6.46 (1.81)
7.42 (1.99)

6.86 (1.82)
6.60 (1.95)

Note*: 5 participants did not report ethnicity and thus percentages for this category only
are based on a total of 95 participants. See Table 1 for variable definitions
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Table 18

Data Collection Method Differences on Outcome Measures
Enhanced

Prescription
Misuse
PDUQ
Abuse/Depend
Rx Symptoms
Alcohol Use
Days Alcohol
Use Month
Abuse/Depend
Alcohol
Symptoms
Other Drug Use
Days Cannabis
Use Month
Cannabis
Abuse/Depend
Symptoms
Trauma
LSC Total
Events
LSC Distress
PTSDSx

Standard

Written

F-value

(p-value)

10.12 (3.94)

8.75 (4.56)

9.49 (4.04)

0.87

.42

2.15 (1.75) a

1.72 (2.05) ab

0.94 (1.19) b

4.49

.01

3.15 (6.08)

3.50 (7.62)

3.14 (7.46)

0.03

.97

0.76 (2.02)

0.91 (2.25)

0.54 (1.82)

0.27

.76

5.91 (11.15)

6.09 (11.77)

2.49 (7.52)

1.34

.27

1.33 (2.20) a

1.66 (2.61) a

0.14 (0.55) b

5.55

.01

12.24 (4.52)

11.16 (5.79)

9.54 (5.57)

2.22

.11

2.63 (0.95)ab
7.06 (5.37)

2.26 (0.86) a
6.69 (5.89)

3.05 (1.01) b
4.09 (5.68)

5.70
2.81

.01
.07

Note: Superscripts that do not match (e.g., a and b) denote groups that are significantly
different from one another as determined by Scheffe post-hoc tests. See Table 1 for
variable definitions.
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Discussion
The present study first sought to determine which demographic, pain-related,
cognitive/social, and stress/emotional factors predict and help to explain the abuse of
prescription opioids among patients in treatment for chronic pain. It was hypothesized
that the traditional, pain, social/cognitive, and emotional factors explored would be
predictive of aberrant prescription opioid use, and that the knowledge of factors related
to stress and emotion regulation would predict prescription misuse beyond more
routinely assessed and established factors. Partial support was found for hypothesis 1.
Personal and family histories of substance use problems were predictive of opioid use
related problems and there was support for emotional ambivalence predicting above
and beyond traditionally evaluated factors. There were inconsistent findings for the role
of personality factors in predicting prescription opioid use problems.
Second, it was hypothesized that the traditional, pain, social/cognitive, and
emotional factors would also be predictive of alcohol and other drug use in this chronic
pain population and that, again, the addition of emotion regulation factors to the model
would explain above and beyond the other factors. Limited support was found for this
hypothesis. Personal and family histories of substance use problems were predictive of
more days of alcohol use during the past month, and emotional ambivalence again
predicted above and beyond traditionally evaluated factors. However, only younger age
predicted whether or not a participant was a current user of alcohol or cannabis.
Third, this study sought to determine whether an innovative, clinically sensitive
interview protocol would enhance disclosure beyond a traditional interview or a
questionnaire by testing different methods of eliciting disclosure of stigmatized
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information (misuse of prescription medication, use of alcohol/drugs, and experience of
stressful events or traumas). It was predicted that participants in the enhanced group
would disclose the most information regarding their prescription misuse, substance use
and abuse, and trauma histories. Further, it was hypothesized that the questionnaire
condition would lead to higher levels of disclosure than the standard interview group.
Partial support was found for this hypothesis. The enhanced group reported more
symptoms of abuse and dependence on their prescription opioids and cannabis than
the written group. Participants in the enhanced group reported more experiences of
trauma than the written group. Results regarding alcohol use, prescription misuse, and
distress over trauma were not supportive of the role of the enhanced method in
improving disclosure.
Prediction of Prescription Opioid Use Related Problems
The first hypothesis posited that knowledge of factors related to stress and
emotion regulation would explain prescription misuse (as evidenced by Prescription
Drug Use Questionnnaire Total scores) and/or prescription opioid abuse or dependence
symptoms, beyond more routinely assessed and established factors. Hypothesis 1 was
partially supported.
Describing prescription opioid use related problems in this sample.
Prescription misuse is defined by risky behaviors related to one’s use of a prescription.
Prescription misuse does not necessarily rise to the level of an abuse or dependence
diagnosis. Examples of risky behaviors included on the Prescription Drug Use
Questionnaire are visiting an emergency room in the past 6 months because of pain,
running out of medication before expected, and using pain medicine to help with other
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symptoms such as anxiety or difficulty sleeping (Compton et al., 2008). Previous
research (Compton et al., 2008) showed a cutoff score of 10 or greater on the
Prescription Drug Use Questionnaire was useful in predicting future clinic-imposed
discontinuation of treatment resulting from patient violations of treatment contracts.
Higher scores on the Prescription Drug Use Questionnaire are indicative of current risky
and problematic behaviors, as well as a likely precursor to the development of an abuse
or dependence diagnoses. Even in the absence of a clinical diagnosis of abuse or
dependence, prescription misuse carries with it interpersonal and health-related risks. It
is interesting to note that as compared to previous research, a higher number of
participants in this study, 49% (n = 49), were

above the cutoff of 10 suggesting

problematic prescription opioid use (Hojsted & Sjogren, 2007).
Regarding reported symptoms of abuse and dependence, it is essential to review
the actual symptoms reported to differentiate misuse from “pseudo-addiction.” “Pseudoaddiction” refers to the expected development of physical dependence to opioids with
ongoing, daily usage. Physical dependence refers to both tolerance to the drug’s effects
(e.g., needing more medication to report feeling the same effect) and withdrawal when
an individual stops using the medication (e.g., sweats, body aches, irritability, etc.;
Weissman & Haddox, 1989). Symptoms of “pseudo-addiction” are inherent in chronic
use of an opioid. Twelve (12%) participants noted tolerance and 31 (31%) reported
withdrawal effects in the current study. However, other DSM-IV-TR symptoms of abuse
and dependence are more consistent with aberrant medication use. Participants
reported an average of 1.59 (SD = 1.74) abuse and dependence symptoms, and many
participants reported symptoms other than tolerance and abuse. Eight (8%) participants
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met criteria for current prescription opioid abuse, and an additional 18 (18%) met criteria
for current prescription opioid dependence; neither of which participants could have met
criteria for without reporting symptoms beyond tolerance and withdrawal. The number of
participants meeting criteria for abuse or dependence of prescription medication has
been debated in the field (Becker et al., 2008; Chabal et al., 1997; Cowan et al., 2003;
Dellemijn, 2001; Hoffman et al., 2005; Hojsted & Sjogren, 2006;), and the current finding
that 25% of participants attending an outpatient, chronic pain clinic met criteria for
abuse or dependence on their prescription opioid medication contributes to this ongoing
debate.
Predicting prescription use related problems. Given that trauma and
emotional regulation styles have been implicated in both the chronic pain and substance
abuse literatures, it was predicted that these variables would play an important role in
understanding the risk of prescription misuse in chronic pain patients. Specifically, it
was hypothesized that higher reported symptoms related to trauma (i.e., higher Impact
of Events Scale Total Scores), higher levels of alexithymia (i.e., higher Toronto
Alexithymia Total Scores), internal conflict over sharing emotions (i.e., higher
Ambivalence Over Emotional Expression Scale Total Scores), and lower reported
likelihood of trying to understand, process, and express emotions (i.e. lower Emotional
Approach Coping Scale Total Scores) would be predictive of prescription opioid misuse
and/or prescription opioid abuse and dependence symptoms.
Traditional factors and prescription use problems: Personal and family history of
substance use problems has a big impact. Personal and family history of substance use
problems were consistently linked to more problems across the three outcome
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measures that assessed problematic prescription opioid use (i.e., Prescription Drug Use
Questionnaire/prescription misuse, total number of abuse and dependence symptoms,
and meeting criteria for opioid dependence). Given that personal history of substance
use problems was the only consistent factor identified in previous research (Turk et al.,
2008), it is not surprising that this variable had a strong, direct correlation with
prescription misuse in this study. In fact, a reported history of substance use problems
means that the participant has already exhibited aberrant drug related behaviors that we
are trying to predict in this study through the use of other factors (e.g., pain, emotional
ambivalence, etc.). Although prescription opioid misuse is unique in that the drug is
medically administered and monitored, the psychopharmacological properties of the
medication, and thus addictive properties, are no different from opioids obtained illicitly
and abused. Additionally, some of the participants who reported previous problems with
substance use had a problem with opioids “off the street”. Participants who have
already had problems with recreational opioid use, are likely at an even higher
increased risk to misuse a medically provided opioid medication.
It is also not surprising that family history of substance use problems was
predictive of prescription opioid use problems. There is strong support in the literature
for family history as a predictor of any substance misuse because of shared genetic
factors, instability in parental relationships, chaotic environments during childhood, and
shared psychological and personality risk factors (Butler et al., 2004; Hojsted & Sjogren,
2007). Genetic vulnerability for substance use related disorders is widely accepted in
the literature, but much of this research has focused on the risk for alcohol related
problems (Heath et al., 1997). It has been suggested that other factors examined in this
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study (e.g., extraversion, psychiatric symptoms, emotional regulation, etc.) may simply
be a result of the same genetic vulnerabilities. In other words, it may be that an
individual is genetically predisposed for extraversion or psychiatric distress, and those
characteristics then lead to substance use problems. In addition to the genetic risks
resulting from family history of substance use problems, it may also be that the mere
exposure to drugs from a younger age, less parental monitoring, more distress resulting
from a chaotic family environment, and neglect or abuse resulting from parental use of
substances leads to younger onset of drug use and thus increased risk of future
substance use problems.
Despite previous evidence that psychological distress leads to increased risk of
prescription misuse (Michna et al., 2004), there were mixed findings in the current
study. Psychiatric distress, as measured by the Brief Symptom Inventory, was shown to
predict prescription misuse, but not symptoms of abuse or dependence. Clinical
impressions of depression, anxiety, or general psychological distress commonly trigger
concerns of substance misuse in practice. Being “under stress” is something that most
people would recognize as a warning sign for potential problematic use, resulting from a
desire to escape the “stress.” Interestingly, psychiatric distress was not predictive of
prescription misuse once family history of substance use problems was controlled.
Although unexpected that psychiatric distress predicted misuse but not diagnostic
symptoms, this may be because psychiatric distress is a temporary state (as compared
to the personality or emotional variables examined in this study). As a temporary state,
distress might lead only to short-term problems of misuse, and not longer-term
problems more consistent with symptoms of abuse and dependence.
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It is interesting to note age and gender were not associated with increased
prescription use problems in this study, despite some previous research suggesting a
link (Michna et al., 2004). The sample in this study was primarily middle-aged and thus
the lack of findings for age may be due to range restriction, rather than a true lack of
utility of age in predicting prescription misuse. Findings have suggested that individuals
on the extremes of the age range (i.e., adolescents/young adults and the elderly) are
most at risk for prescription misuse, and the current sample had very few individuals
who were at those extremes. In regards to gender, despite previous research
suggesting that men are more likely to abuse or become dependent on substances,
recent evidence suggests that gender differences may not exist when examining use of
prescription opioids (Jamison, Butler, Budman, Edwards, & Wasan, 2010). In fact,
recent research by Jamison et al. (2010) suggests that there is likely a similar rate of
prescription misuse between genders, but the way in which it is expressed likely differs.
For example, Jamison et al. suggest that at the symptom level, women may report more
distress related to misuse while men might report more environmental consequences of
their misuse. Thus, when prescription use problems were examined at the nominal level
in the current study, misuse or no misuse, any possible gender differences were likely
hidden.
Pain and prescription use problems: Pain is not as important as expected. Pain
did not play a substantial role in predicting prescription use related problems. The only
pain related finding, was that anxiety over the experience of pain symptoms and belief
of inability to cope with or reduce pain symptoms, were linked to a higher likelihood of
meeting diagnostic criteria for prescription opioid dependence. It is notable that pain
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anxiety was not related to prescription misuse (i.e., Prescription Drug Use
Questionnaire) or total number of abuse and dependence symptoms, but this may be
because those participants with pain anxiety were engaging in chronic overuse of
medication consistent with a dependence diagnosis (e.g., more tolerance, inability to
quit medication use, withdrawal symptoms, etc.) and not risky behaviors (i.e.,
prescription misuse and/or abuse symptoms).

Increased helplessness over pain

symptoms likely leads to increased use of medication to try and reduce pain because
patients feel incapable of managing the pain through psychological (e.g., relaxation,
imagery, pacing) or physical (e.g., stretching, massage, etc.) means. Despite a link
between pain anxiety and a diagnosis of prescription opioid dependence, pain anxiety
did not predict dependence diagnosis after accounting for family history of substance
use problems.
Under-treatment of pain and higher pain severity have been noted as likely
reasons for increased opioid medication use, yet there were minimal relationships found
between pain variables and prescription use related problems in this sample. Weissman
and Haddox (1989) opined that prescription use related problems cannot be identified in
patients whose pain is not being treated adequately because aberrant behaviors result
from a desire to treat the pain, rather than a desire to feel a high from the drug. It has
further been speculated, without research support, that individuals who are using
prescription opioids to treat pain cannot experience the “high” from the medication.
Despite the widespread belief in Weissman and Haddox’s (1989) theory, Weissman and
Haddox had not experimentally examined this theorized relationship of pain and
prescription use related problems. Although the theory that under-controlled pain leads
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to increased prescription use has continued to be widely believed, it has not been
examined using standardized pain measures. The finding that pain played a minimal
role in predicting prescription use related problems in the current study is unexpected,
and likely suggests that under-treated pain may not play as large of a role in the
prescription misuse and diagnostic symptoms as previously hypothesized. It may be
that the presence of pain and not the severity or distress from pain matters most. Thus,
in this sample, in which all participants were taking prescription opioids to treat some
degree of pain, no differences should be expected. It may also be that because the
sample of patients who participated in this study were self-selected, a biased sample of
pain severity was created because those individuals with more severe and unmanaged
pain are unlikely to volunteer to sit for 1.5 to 2 hours to engage in the current study.
Social/cognitive factors and prescription use problems: Inconsistent, minimal
findings. Within the social/cognitive predictors, the findings were inconsistent across the
categories of prescription opioid related problems (i.e., prescription misuse, total
number of abuse and dependence symptoms, and dependence diagnosis). The
social/cognitive differences between prescription misuse and prescription related
symptoms of abuse and dependence were noteworthy. The same personality factors
did not play a role in misuse, as compared to symptoms of abuse and dependence, and
none of these social/cognitive variables remained significant when controlling for family
history of substance use in the regression models. Cognitive factors that warrant further
examination are neuroticism (i.e., lower emotional stability), openness to experience,
and extraversion.
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Neuroticism was predictive of total number of abuse and dependence symptoms
and dependence diagnosis, but only in the absence of controlling for other factors such
as family history and psychiatric distress. Although neuroticism has not previously been
identified as a predictor of prescription use problems in chronic pain patients, the finding
is not surprising given that neuroticism has been found to have a predictive relationship
with other substances of abuse. Neuroticism is a personality trait defined by a
consistent, enduring tendency to experience negative emotional states, high reactivity to
stress, and difficulty delaying gratification of desires. As with psychiatric distress, higher
substance use in individuals that are high in neuroticism may be due to an attempt to
escape or avoid negative internal emotional states. It is not surprising that it was not
predictive of prescription opioid symptoms of abuse and dependence after controlling
for psychiatric distress. Although the measure of psychiatric distress in this paper was
aimed at current levels of psychiatric problems, those individuals who are neurotic are
likely to rate themselves as more psychiatrically distressed at all times. After accounting
for psychiatric distress, the relationship of neuroticism to prescription opioid symptoms
was no longer evident.
Openness to experience was linked only to a higher number of total abuse and
dependence symptoms, a relationship that was not anticipated, and only existed in the
absence of controlling for other predictors. Increased openness to experience may
explain increased engagement in risky behaviors (e.g., driving while feeling impaired
from use or going to school or work while feeling impaired by their prescription), as it is
often defined as an increased need for variety and ongoing curiosity. It may be that
openness is related to an increased willingness to experiment with medication use,
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and/or curiosity about medication which then leads to use of higher or more frequent
doses than prescribed. Given the lack of previous findings regarding openness and the
limited theoretical reasons for its role in prescription misuse or use of other substances,
replication to determine whether this finding is consistent across samples is necessary.
Extraversion was linked only to prescription misuse, as measured by the
Prescription Drug Use Questionnaire, and only when the role of other factors was not
controlled. Extraversion has not been previously studied in this population, but it is not
surprising that higher levels of extraversion are correlated with increased prescription
misuse, as there is evidence for the relationship of extraversion to problems with illicit
drugs (Agrawal, Jacobson, Gardner, Prescott, & Kendler, 2004; Gorman & Derzon,
2002). Extraverts are typically outgoing, adventurous, and depend on external stimuli for
excitement. As a result, it has been suggested that extraverts are more likely to be
adventurous with their willingness to experiment with drugs. Additionally, Depue and
Collins (1999) found that at a neurological level, extraverts’ dopamine systems are more
responsive to pleasurable stimuli. This higher reactivity of the dopamine system to
pleasurable stimuli likely leads to a higher responsivity to the potential pleasurable
experience of a “high” from prescription opioids, resulting in increased misuse of the
medication.
Emotions and prescription use problems: Emotional ambivalence is an important,
new predictor. The emotional variables were of particular interest, and emotional
ambivalence was the most consistent predictor of prescription opioid use related
problems. Higher levels of internal conflict over sharing one’s emotions was linked to
more prescription use related problems for all three outcome categories (i.e.,
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prescription misuse, total number of abuse and dependence symptoms, meeting criteria
for prescription opioid dependence). Even after accounting for other predictors,
emotional ambivalence remained predictive of prescription misuse and total number of
prescription opioid abuse and dependence symptoms. This means that even if we know
whether someone has a family history of substance use problems, emotional
ambivalence is able to add unique information to help us predict above and beyond the
knowledge of family history.
Emotional ambivalence reflects ongoing internal conflict about the desire to hide
emotions, despite external circumstances that demand disclosure, and/or regret over
decisions to disclose feelings. As with psychiatric distress, it is likely that the ongoing
stress resulting from emotional ambivalence motivates the individual to quell his or her
internal experience further. For individuals high on emotional ambivalence, prescription
opioids may provide a way to suppress his or her internal, emotional conflict as the
prescription is readily available and many people experience a calming and/or euphoric
effect from opioids. It is notable that the relationship between emotional ambivalence
and prescription use related problems remained even after accounting for psychiatric
distress. This finding suggests that the trait-like characteristic of emotional ambivalence
is qualitatively different from the state-like measure of general psychiatric distress. The
consistent findings, across outcomes and after controlling for other important variables
like family history, found with emotional ambivalence suggests that it plays a more
substantial role in the prediction of prescription misuse than general psychiatric distress.
A higher level of alexithymia was linked to both higher prescription misuse and
diagnosis of opioid dependence. However, alexithymia was not predictive of either

111
outcome after accounting for the role of family history of substance use problems, pain
variables, and social/cognitive variables.

Although alexithymia might predict

prescription use related problems in the absence of other variables, the utility of
alexithymia is only evident in the absence of more traditionally understood predictors. It
is not surprising that alexithymia was not predictive of prescription misuse after
controlling for other factors because of its high correlation with general psychiatric
distress (i.e., Brief Symptom Inventory Global Severity Index), which was controlled for
in this study. It is likely that the link between alexithymia and psychiatric symptoms lead
to alexithymia being redundant, and lacking utility, when psychiatric symptoms were
present in the model.
There were limited findings regarding trauma related symptoms. Trauma
symptoms were only linked to prescription opioid dependence, and only in the absence
of controlling for other factors. It may be that that trauma related symptoms are
predictive of more severe and chronic symptoms, as measured by meeting criteria for
opioid dependence, rather than an engagement in risky behaviors, as measured by
prescription misuse or total number of abuse and dependence symptoms (note: abuse
symptoms are generally categorized as risky behaviors; whereas dependence is
generally categorized as more chronic physical, social, and personal problems).
Individuals with a family history of substance use have consistently been found to have
higher rates of lifetime traumas (Maker, Kemmelmeier, & Peterson, 1998; Murphy,
Jellinek, Quinn, Smith, Poitrast, & Goshko, 1991), and the lack of findings related to
trauma may have resulted from controlling for family history of substance use problems.
Additionally, the rate of reported trauma experiences was high in this study, and likely
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reflects the unique characteristics of this sample. It may be that trauma, like pain, was
affected by a restriction in range due to the uniqueness of the sample. In a sample with
more varied histories of trauma, in which some participants report little to no major
traumatic life events, participants with extensive trauma histories may be qualitatively
different from participants who have not experienced many major stressors. Although
not reported in the results, both stress related symptoms from trauma experience (i.e.,
Impact of Events Scale) and total number of life stressors (i.e., Life Stressors Checklist)
were evaluated and resulted in similar findings.
An individual’s tendency to evaluate or share emotional experiences (i.e.,
Emotional Approach Coping Scale) was not predictive of any of the prescription use
related problems. The lack of findings related to one’s tendency to share his or her
emotional state, despite the substantial role of emotional ambivalence in predicting
prescription use related problems, suggests that it is the conflict over expressing
emotions (i.e., Ambivalence Over Emotional Expression), rather than the actual
tendency or likelihood to process and share one’s emotions with others (i.e., Emotional
Approach Coping Scale) that leads to more emotional distress and increased
prescription misuse. In other words, it is the internal conflict and not the actual choice to
express emotions or seek support that matters most in predicting prescription misuse.
Summary of prescription opioid use problems. The findings clearly showed
that personal and family history of substance abuse contribute a great deal to the
prediction of who may be at highest risk for prescription misuse, total number of opioid
abuse and dependence symptoms, and meeting criteria for dependence on prescription
opioids. In a 2008 review of the literature on prescription use related problems in
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chronic pain populations prescribed long-term opioids, it was found that the only clear
predictor of current or future use related problems was previous history of substance
use problems (Turk et al., 2008). Additionally, as noted earlier, most studies included in
this literature review were based on record reviews, and thus lacked the ability to
determine social or personal impacts of prescription use and/or misuse on patients’
lives. The current findings that suggest parental history of substance use problems,
current psychiatric symptoms (rather than psychiatric diagnoses as noted in Michna et
al., 2004), higher levels of pain anxiety, higher levels of alexithymia, higher levels of
extraversion, and higher emotional ambivalence may predict increased prescription
opioid use problems expanded upon the previous research. These findings provide
medical care providers treating chronic pain patients a wider net of risk factors that
should be evaluated and monitored when prescribing long-term opioid medications. It is
especially important to note that emotional ambivalence was predictive of prescription
misuse above and beyond the roles of traditional, pain, and social/cognitive factors.
For prescription misuse and total number of symptoms, it was found that
emotional ambivalence was the only clear emotional predictor after controlling for more
basic, or previously researched variables. These findings suggest that conflict or
distress over whether or not to share internal emotional experiences, and/or feelings of
regret over sharing (i.e., emotional ambivalence; Ambivalence Over Emotional
Expression Questionnaire), is more important than a limited understanding of one’s
emotions (i.e., alexithymia; Toronto Alexithymia Scale), a general tendency to choose
not to share one’s emotions (i.e., Emotional Approach Coping Scale), or symptoms
related to trauma. Thus, identifying participants who report distress over the potential
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results of sharing their feelings, do not feel capable of sharing their feelings, and/or
experience regret over times that feelings have been shared are at higher risk of
misusing their prescription. Emotional ambivalence has previously been related to a
lower quality of life and poorer psychological well-being (Carson et al., 2007; Lu, Uysal,
& Teo, 2011), and it may be that these participants have a more difficult time coping
with their chronic pain condition and the effect that it has on their lives, leading to more
prescription opioid misuse. It may also be that individuals high on emotional
ambivalence misuse prescription opioids to distract from a distressing internal conflict
regarding emotional expression. None of the emotional variables evaluated in this study
have previously been shown to have a relationship with prescription opioid use related
problems in chronic pain patients, despite literature suggesting they are related to the
development and maintenance of chronic pain (Ak, Sayer, & Yontem, 2004; Burba et
al., 2006; Celikel & Saatcioglu, 2006; DeGenova et al., 1994; Leitenberg et al., 1992;
Lumley, Neely, & Burger, 2007) and increased risk of abusing other substances
(Handelsman et al., 2000; Pinard et al., 1996). The finding that emotional ambivalence
was predictive of prescription misuse and total number of prescription abuse and
dependence symptoms, even after controlling for traditional, pain, and social/cognitive
factors is novel and provides promising evidence for the role of emotions in predicting
aberrant prescription use.
The current findings regarding the rate of prescription opioid use related
problems in this population reinforces the fact that patients being prescribed long-term
opioid treatment must be effectively and routinely screened for risk factors. It is
important to note, that although the traditional factors can explain much of the variance
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in this model, there are still instances in which clinicians are in the position of predicting
whether someone might be at risk for developing a substance problem without ever
having used previously, and/or without knowledge of their parents’ substance use.
Thus, absence of personal or family history of substance use problems does not imply a
complete lack of risk, and the current study began to identify additional variables that
could help to explain what additional characteristics make someone more at risk for
developing prescription opioid misuse problems. Although past history of substance
abuse can provide pragmatic information to clinicians who are prescribing and
monitoring the use of prescription opioid medications, prior history of substance abuse
is not theoretically descriptive, and cannot explain what characteristics have contributed
to that individual being at higher risk of developing prescription misuse problems. Prior
history of substance abuse may be useful in a clinical setting, in informing the decision
to prescribe or not prescribe medication; however, it does not help us to understand
why that person is more at risk developmentally. A theoretical understanding of the
personality characteristics, and emotional styles can contribute to increased risk could
help inform future prevention and treatment efforts.
Prediction of Alcohol and Cannabis Use in Chronic Pain Patients
The

second

hypothesis

posited

that

traditional/demographic,

pain,

social/cognitive, and emotional factors would be predictive of individuals who were
using alcohol and other drugs (as evidenced by self-reported days of use during the
past month on the SCID). Hypothesis 2 was partially supported.
Substance use in the sample. Use of alcohol or other drugs while prescribed
an opioid can lead to ineffectiveness of the medication in treating pain, and serious
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health risks. Consequently, evaluation of other substance use is essential in
understanding the full picture of risky prescription opioid use. At the time of study
participation, the rates of meeting current criteria for abuse or dependence on the
following substances were substantial: 14 (14%) on alcohol, 17 (17%) on cannabis, 5
(5%) on cocaine, 3 (3%) on opioids other than their prescription, and 3 (3%) on
sedatives. Thus, it is essential to also understand what risk factors may contribute to
increased likelihood of using alcohol and other drugs in a chronic pain population. Given
the small number of participants using other drugs during the past month, only alcohol
(41; 41% of participants) or cannabis (25; 25% of participants) use during the past
month were evaluated. Hypothesis 2 was partially supported for the continuous
measure of days of alcohol use; however, there was no support for hypothesis 2 when
examining the dichotomous measures of being an alcohol user or cannabis user.
It is first interesting to note that there were higher rates of alcohol and other
substance use in our sample than reported in previous studies (Edlund et al., 2007).
This may be a result of the method used to assess substance use in the current study.
Many of the previous studies reporting substance use in chronic pain patients were
assessed using urine drug screens, rather than self-report. Urine drug screens are
limited by the length of time which can be evaluated as many drug tests provide
information only on the last 3-5 days of use, as compared to the full self-reported use
history and past 30 day use report collected in this study. Additionally, the urine drug
screens were often conducted by individuals directly involved in the patients’ care;
therefore, there were more motivating factors in previous studies to hide other drug use,
because in most programs drug use could lead to expulsion from the program. Given
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the confidentiality of the current study, there were fewer motivating factors to hide
substance use. As a result, the current study may be a better estimate of the actual
substance use in an urban, chronic pain patient population.
Days of alcohol use during the past month: History of substance use and
emotional ambivalence are still important. Many of the findings for days of alcohol
use during the past month were similar to those of prescription opioid use related
problems. Personal and family history of substance use problems and increased
psychiatric distress were associated with more days of alcohol use during the past
month. Alcohol related problems have been the primary focus of previous research
findings that suggest a substantial role of family history in predicting increased risk of
misuse, and thus this relationship was anticipated (Heath et al., 1997). It is again likely
that the genetic predisposition, in addition to environmental factors through
development (e.g., early exposure to alcohol/drugs, structure and boundaries in the
home, attachment, etc.), put individuals at a much higher risk of developing a multitude
of substance use and psychiatric problems.
As with prescription opioid use related problems, pain and social/cognitive factors
played a minimal role in predicting increased days of alcohol use during the past month.
Pain catastrophizing was found to predict more days of alcohol use, but this relationship
was not maintained after accounting for other factors. The link between pain and
increased use was anticipated, based on the concept that substances may be used to
relieve physical pain and emotional distress. As with prescription opioid use problems, it
was again surprising that more consistent findings between pain and increased alcohol
use were not found. It may again be that the severity of pain necessitated by being
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referred to the chronic pain clinic sets a rather high minimum level of pain, while the
self-selection into a study which requires sitting for 1.5 to 2 hours sets a maximum cap
on severity of pain. It would be interesting to determine whether a similar study,
repeated in a primary care clinic in which the minimum pain threshold for treatment is
much lower, would still result in a lack of findings for pain as a predictor of alcohol use.
Regarding social/cognitive factors, it was found that less agreeableness and
higher neuroticism were predictive of more days of alcohol use. Neuroticism was only
linked to higher days of alcohol use in the absence of other variables. Thus, the utility of
neuroticism as a predictor of days of alcohol use only exists when family history of
substance use and pain catastrophizing cannot be determined. Neuroticism has long
been identified as a risk factor for problematic alcohol use (Agrawal, Gardner, Prescott,
& Kendler, 2005; Sher, Bartholow, & Wood, 2000; Spotts & Shonts, 1984; Spotts &
Shonts, 1991), and it is surprising that neuroticism did not predict above and beyond
more traditionally evaluated factors in this sample. The limited findings related to
neuroticism in this sample may be due to the way that alcohol use was operationalized
in this study. As opposed to previous studies which have examined problematic use
behaviors and/or diagnostic criteria for abuse or dependence on alcohol, days of alcohol
use during the past month might not accurately capture participants who are engaging
in problematic use. Neuroticism may be linked more directly to problematic use rather
than frequency of use. Lower agreeableness remained predictive of increased days of
alcohol use above and beyond the role of family history of substance use problems and
pain. One of the two items that was used to assess agreeableness was being “critical or
quarrelsome” and it may be that individuals who are using alcohol more often,
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suggestive of potential alcohol use problems, rate themselves as more quarrelsome
because they are often defending their use of alcohol, rather than low agreeableness
leading to increased alcohol use.
Also interesting is the finding that increased emotional ambivalence was
correlated with increased days of alcohol use, as this has not previously been identified
as a predictive factor for alcohol use. The finding that emotional ambivalence was linked
to both prescription opioid use related problems and increased alcohol use suggests the
importance of further examination of this factor as a predictor for substance use in
general. The finding emotional ambivalence was able to predict increased alcohol use
after controlling for family history of substance use, pain, and social/cognitive factors
again suggests that it is internal conflict over emotional expression that is linked to
actual substance use in a chronic pain sample. There was no support in this study for
the role of alexithymia, ongoing distress related to trauma experiences, or the tendency
to express emotions in predicting alcohol use. This finding lies in contrast to previous
research on alcohol use which has found higher levels of alexithymia as predictive of
more alcohol related problems (Handelsman et al., 2000; Pinard et al., 1996). It may
again be a result of the way in which alcohol use was measured which resulted in an
inaccurate picture of alcohol related problem behavior. It may also be that alexithymia
does not play the same role in predicting alcohol use problems in a chronic pain sample
as it does in the general population.
Predicting use of alcohol during the past month: All you need is age. Only
younger age was predictive of being an alcohol user. This suggests that age, in the
absence of any other potential risk factors, can give the best picture of who might be
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using alcohol while receiving prescription opioids. Despite lacking participants on the
extremes of the age range (i.e., no adolescent and few elderly patients), it still seems
that even a few years difference in age can predict the likelihood of being a current
alcohol user. In fact, knowing only age led to the correct classification of almost 3/4s of
patients as current alcohol users in this study. As alcohol is often used socially, it may
be that younger patients are more likely to drink at least once per month because of the
increased social demands to drink often associated with younger age. Additionally,
younger individuals have less occupational and family demands and are therefore more
able to drink without consequences resulting from ignoring those demands.
The reason for differences between the hierarchical regression of days of alcohol
use, versus the categorical decision of whether or not someone is an alcohol user, may
be due in part to the fact that someone who uses alcohol one or two days per month,
likely looks very different from someone who is using 15 or 30 days per month. In the
categorical model of alcohol user versus non-user, participants who used alcohol one
day during the last month were lumped into the same group as regular or daily users.
Predicting use of cannabis during the past month: All you need is age.
Surprisingly, the only clear predictor of being a current cannabis user was being
younger. This finding suggests that it is imperative to be aware of increased risk of
younger chronic pain patients to be using illicit drugs, and cannabis in particular. This
finding also suggests that regardless of having other characteristics that had been
hypothesized as being predictive of illicit drug use, we may only need to know age to
know who needs to be monitored more closely for illicit drug use while receiving longterm opioid treatment for chronic pain. Perhaps younger patients at a chronic pain clinic
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are more likely to have more active social lives, which lead to more availability of illicit
drugs that are not as easily accessed by older patients.
Methodology Differences in Data Collection
As this study shows, aberrant prescription use and use of alcohol and other
drugs while taking prescription opioids are a substantial risk in chronic pain populations,
and there is an obvious need to be able to collect accurate information about these
behaviors from patients. Appropriate patient care and targeting of monitoring
interventions is limited by the accuracy of information received, and there are very real
and serious health risks associated with these problematic behaviors. Typical medical
care relies upon a mix of patients’ self-reports and clinical providers’ impressions of the
patients. It is especially difficult to gain accurate information regarding prescription
misuse and alcohol and other drug use when there are strong motivating forces for
patients to hide their use from their medical care providers. A patient’s disclosure that
he or she is misusing a prescription or using other substances may lead to restrictions
of their opioid medications and/or being removed from the treatment program. Thus,
efforts to continue to improve the methods used to improve the accuracy of patients’
self-reports are necessitated.
Based on findings from a previous study conducted by Sander et al. (2008) which
examined methods for improving trauma disclosure in a college population, it was
predicted that the enhanced assessment method would lead to more disclosure of
trauma, prescription misuse and abuse/dependence symptoms, and alcohol and other
drug use than a standard interview assessment method and a written assessment
method. Based on findings by Newman et al. (2002), which examined self-reported
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substance use and risky HIV related behaviors and found that the more distance from
the other person (e.g., computer is better than phone, phone is better than in-person),
the more reported risky behaviors, it was predicted that the written assessment group
would disclose more problematic behaviors than the standard interview assessment
method. It is important to note that in this study it was assumed that reports of more
misuse of prescription medications, higher number of abuse and dependence
symptoms on prescription opioids, more frequent use of substance use, or higher
number of reported traumas and trauma symptoms are considered to be more accurate
information because of the usual bias for individuals to minimize these responses.
Hypothesis 3 was partially supported. In contrast to hypothesis 1 and 2, hypothesis 3
was examined through an experimental design, employing random assignment to the
assessment groups. The experimental design allows the interpretation that any
assessment group differences found were likely due to the group assignment.
As predicted, the enhanced assessment method group reported more abuse and
dependence symptoms on their prescription opioids than the written group; however, no
differences were found between the standard interview assessment group and the
written group. Thus, the enhanced techniques of meta-communication, further
questioning of participants’ responses, and normalizing problematic behaviors may
have led to participants’ greater likelihood to share problematic symptoms related to
their prescriptions. Interestingly, no group differences existed for prescription misuse as
measured by the Prescription Drug Use Questionnaire. Questions of misuse are less
stigmatizing than symptoms of abuse and dependence, and it may be that no
differences were found between groups because there was not as much motivation for
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participants in any of the groups to minimize their responses. Future exploration of this
hypothetical explanation is necessary, but if supported this may suggest that it would be
more efficient to question participants on misuse behaviors than symptoms of abuse or
dependence because no specialized assessment method is necessitated.
Unexpectedly, there were no differences in reported days of alcohol use or
symptoms of abuse or dependence on alcohol. This finding may also be attributed to
the fact that alcohol use is a relatively socially acceptable behavior and participants
across all three groups may have had no motivation to minimize their use or behaviors
related to alcohol. As predicted, there were group differences in regards to cannabis
use, but as with prescription use, the differences were found only with self-reported
symptoms of abuse and dependence on cannabis, and not the less stigmatizing report
of use. Specifically, the enhanced group reported more cannabis related abuse and
dependence symptoms than the written group. Surprisingly, the standard interview
assessment group also reported more cannabis abuse and dependence symptoms than
the written group. Thus with cannabis use, participants were more likely to report
symptoms of abuse and dependence when interviewed, rather than when asked to
respond to a written questionnaire. This finding is in contrast with Newman et al.’s
(2002) finding that more distant methods of disclosure lead to higher reports of
stigmatizing behaviors.
Finally, there were inconsistent results regarding trauma. It was found that as
predicted, the enhanced group shared marginally more trauma related symptoms on the
Life Stressors Checklist than the written group (no difference existed between either
enhanced or written and the standard group). In contrast, the written group disclosed
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higher current distress over their traumatic experiences as measured by a 1 to 5 scale
than the standard group (no difference existed between the written or standard group
and the enhanced group). Taken together, these findings regarding trauma symptoms
and distress suggest that the enhanced group was more consistently related to higher
report of trauma and importantly symptoms related to trauma, but that the addition of a
written scale rating distress may be useful. It may be that the distress rating scale was
better understood and conceptualized when participants could actually look at the
anchors of “no distress” to “extremely distressed”. It is also worthwhile to note that the
standard group was not particularly effective in gathering trauma related symptoms.
These findings are important because they stand in contrast to the standard
interview techniques commonly methods in medical settings. This suggests that it is
important that continued efforts are made to evaluate and improve interviewing styles,
and that there is promise for engaging in meta-communication, normalizing of
problematic behaviors, and persistent questioning and following of openings in patients’
responses to yes/no questions. It is also essential that efforts are made to make these
methods marketable to and useful for busy chronic pain medical treatment providers.
Considerations of appropriate training in these techniques would be essential to
effective use of the enhanced strategies. Additionally, given the extra time needed to
employ the enhanced techniques, it may be useful to target the use of these techniques
to patients who are high on at least one of the predictive variables identified in
hypotheses 1 and 2.
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Limitations
One limitation of this study was that it was based fully on self-report. Self-report
can be biased because retrospective reporting is subject to a participant’s ability to
remember days of use or occurrence of symptoms, as well as potential motivations to
actively withhold information (e.g., stigmatizing, guilt, worries about the consequences
of sharing aberrant behaviors, etc.). Given the sensitive nature of the questions asked in
this study, it is likely that many participants experienced some hesitance to share
accurate information about aberrant prescription opioid use, use of alcohol or other
drugs, and trauma histories. Additionally, almost all of the self-report was conducted via
questionnaires, which can be limited by the participants’ ability to understand and
accurately respond to questions and rating scales. Thus, although efforts were made to
improve the validity of participants’ self-reports through ensuring confidentiality,
anonymity, and the researchers’ presence throughout the study to answer any
questions the participants had, the accuracy of the information cannot be ensured. Also,
at a very basic level, study participation was based on the self-report of the participant
that he or she was a current client of the pain management clinic and had been
prescribed an opioid for longer than 3 months. Unfortunately, given the need for
anonymity, the researchers had to base their decision on whether the individuals
qualified for the study on participants’ self-report and the researchers’ own judgment of
whether or not the potential participant was being honest.
The current study was also limited by the study design which used a point
prevalence model to examine the correlations between potentially risky personal
characteristics and current problematic use at a single time point. The current study
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design does not exclude the possibility that problematic prescription use has some
influence on personality or emotional factors and thus rather than being predictive of
future misuse, the identified characteristics may simply be a signal of current
problematic use. For example, it could be that current prescription misuse leads to more
conflict over emotional expression rather than the reverse. Importantly, because this
study was not longitudinal, interpretations of the results of this study are unable to
answer the questions of whether or not an individual should or should not be prescribed
opioid medications and who will abuse their medications. As a result, we were only able
to identify variables that are likely descriptively useful in understanding people who
might misuse prescriptions and to determine whether these factors (e.g., emotional
ambivalence, personality factors) actually lead to increased misuse, a prospective study
must be conducted.
Another major limitation of this study was that participants self-selected to
participate. Recruiters actively tried to engage with any patient who entered the waiting
room during recruitment periods and brochures were available to all patients, there may
still be unique factors about those participants who were willing to participate in a study
about substance use, trauma, and prescription use. It may be that the individuals who
self-selected into the study were more comfortable sharing aberrant prescription use
and/or substance use. It may also be that participants who had even more misuse of
their prescriptions or more substance use chose not to participate because of fears over
the potential consequences despite the guaranteed anonymity. Further, it may be a
healthier sample that self-selected into the study, because participants with more
severe pain conditions may have felt incapable of sitting in a study session for up to 2
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hours. Given that medical record reviews were not conducted on the full clinic
population, it is unclear how this self-selected sample might compare to the entire
chronic pain management clinic.
This study was also limited by the inability to consult with the participants’
treatment providers or use medical records. Unfortunately, because of the IRB issues
related to maintaining the anonymity of the participants, we were unable to collect
participant names to be able to match up doctors’ ratings or access medical records.
Having access to the medical records would have allowed verification of self-reported
aberrant behaviors such as requesting another prescription before the previous one
should have ended, requesting frequent dose increases, requesting shorter acting or
more commonly abused opioid medications, etc. Having access to the medical records
also would have allowed for exploration of the physicians’ recorded concerns about
patients’ potential for aberrant behavior.
Finally, the results of this study likely only generalize to patients receiving longterm opioid prescriptions for chronic pain who are being treated in an urban, low-income
pain management clinic. Additionally, the majority of the participants were AfricanAmerican which likely contrasts from ethnic make-up of many chronic pain management
clinics. It is unclear based on this single study whether the results would be consistent
in a primary care treatment center, in clinics treating patients primarily of other
ethnicities, or in clinics treating non-urban or middle to higher income patients. Also,
given that the identification of emotional ambivalence is a novel finding, replication of
this study is warranted to ensure the finding was not erroneous or sample specific.
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Future Directions
Future studies should employ longer-term tracking of chronic pain patients to
improve our understanding of who develops problems with aberrant prescription opioid
use, symptoms related to prescription opioid use, or concurrent use of alcohol and other
substances. Given the point in time strategy design of the current study, the direction of
the relationships between those variables termed for study purposes as predictors and
those termed as outcomes are unknown. A point in time strategy is often used in early
research on a topic, but the next step is to evaluate and track the identified personal
characteristics that may signal potential problematic future use beginning at the initiation
of long-term opioid treatment.
The focus of most of the research in this area has examined either individuals
who were receiving care through pain management clinics or those seeking treatment in
an opioid management setting (e.g., methadone clinic); however, the rate of prescription
misuse in individuals receiving pain medication through primary care is even less
understood. Given the lower degree of monitoring due to time constraints and limited
experience and training with a chronic pain population, there may be increased risk of
aberrant medication related behavior in a primary care setting. It is additionally
important to consider the use of opioid medications in a primary care setting as patients
receiving treatment through primary care likely constitutes a large proportion of
prescriptions for opioid treatment.
Future studies should also evaluate physicians’ ratings of how likely they believe
their patients are to be misusing their prescription medication, meeting criteria for abuse
or dependence on their prescription opioid, and using alcohol and illicit substances
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along with their prescription opioid would add substantially to the understanding of how
decisions about patients are made in actual practice. Current practice guidelines
suggest that a thorough evaluation of risk for aberrant prescription opioid use is
conducted at the beginning of all patients’ treatment programs (Chou, Ballantyne,
Fanciullo, Fine, & Miaskowski, 2009a; Chou et al., 2009b), but given the weak evidence
cited in those guidelines for any particular characteristics that define risk, it would be
useful to understand how risk assessment is currently being practiced. This would allow
a baseline for understanding how accurate doctors are in making decisions about who
is at risk of future problematic prescription use and/or who is currently engaging in
problematic use behaviors. Further, understanding where potential gaps between
research evidence for risk factors and providers’ knowledge could help inform needs for
further dissemination of findings to physicians treating chronic pain patients with longterm opioid treatment.
Future studies should evaluate both self-report methodologies and biological
markers of alcohol and drug levels. Employing both self-report and biological markers
would allow a reference point for accuracy in self-reported use. Although this would
strengthen the faith in the outcome measures to the predictive models, this would be
especially important for improving our understanding of which methodological
assessment groups produced the most accurate reports of use. In the current study, the
possibility that participants in the enhanced group were exaggerating their use rather
than being more comfortable sharing prescription abuse and dependence symptoms,
although unlikely, is left open.
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The results of this study suggest that emotional styles contribute uniquely to the
prediction of prescription opioid use related problems as well as increased days of
alcohol use. In particular, these findings warrant further examination of emotional
ambivalence and alexithymia to determine whether the findings in this study can be
replicated. The findings of this study also suggest that it is internal conflict rather than
actual actions related to emotional expression that can be predictive of prescription
misuse and use of alcohol while taking prescription medication. Therefore, it may be
useful to further explore whether conflict over addressing problems in relationships
and/or the internal experience of active attempts to avoid experiences which may elicit a
need to decide whether to express oneself. The ultimate goal of identifying risk factors
is to integrate assessment of those risks into clinical practice. It is imperative to develop
methods that can quickly and routinely assess these emotional risk factors. Given that
observational and interview techniques are the predominant method of data collection in
a clinic setting, it will be essential to develop similar means for assessing emotional
styles.
Most importantly, further research and development must be done on the
techniques that can be employed to prevent the development of problematic
prescription opioid use in chronic pain populations after identifying patients who are atrisk for problematic use. There are four main areas of intervention that have been
identified recently in the literature: a) monitoring through random drug screens and
continued evaluation with the treatment provider for signs of aberrant use

(Bailey,

Hurley, & Gold, 2010; Chou et al., 2009a; Jamison et al., 2010; Markowitz, Francis, &
Gonzales-Nolas, 2010; Webster & Fine, 2010); b) medication based changes (e.g.,
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changing the pharmaceutical makeup of the medication to make it tamper proof,
providing only long-acting opioids to clients who are identified as higher risk, providing
only scheduled dosing of medications with no “as needed” dosing; Bailey, Hurley, &
Gold, 2010; Walwyn, Miotto, & Evans, 2010; Webster & Fine, 2010); c) contracting for
appropriate medication use (Bailey, Hurley, & Gold, 2010; Markowitz, Francis, &
Gonzales-Nolas, 2010); and d) psychological interventions, including psychoeducational and cognitive-behavioral techniques focused on the interaction of pain and
addiction (Jamison et al., 2010). These forms of intervention are relatively new and not
well studied in this population. In fact, as mentioned previously, the current practice
guidelines suggest that although it is extremely important to monitor, track, and
intervene with patients who are at-risk or actively engaging in aberrant use, a clear
understanding of what “at-risk” is and how effective these intervention techniques are at
preventing aberrant medication behavior is lacking. Additionally, given the identification
of emotional ambivalence as an identified risk factor in the chronic pain population,
further efforts should be made to develop and integrate emotionally-focused treatment
approaches into the psychological interventions.
Summary
This study at the most basic level provided another sampling of the rate of
problematic prescription opioid use in chronic pain patients. Previous rates of
problematic prescription use have ranged from 0 to 50% (Hojsted & Sjogren, 2006). The
wide ranges of previously reported rates are based on both inconsistent definitions of
problematic prescription use as well as variations in study methods. Given that the
current study assessed problematic prescription use using two definitions (i.e.,
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prescription misuse as measured by the Prescription Drug Use Questionnaire and
number of symptoms of DSM-IV-TR abuse and dependence symptoms) and found that
approximately a quarter to a half of participants were displaying some form of
problematic prescription opioid use is likely a better estimate of the actual problematic
use in a chronic pain population prescribed long-term opioids.
It is also significant that this study replicated the findings that past history of
abuse of substances and/or family history of abuse of substances are predictive of
prescription misuse (Turk et al., 2008). This finding provides stronger evidence that
patients receiving opioid medications need to be screened for previous substance
abuse and family substance use. In addition to reinforcing and replicating the role of
personal and family history of substance use problems, this study sought to explore
theoretical factors that may contribute to understanding and describing the development
of prescription opioid dependence. To this end, this study provided new evidence for the
role of emotional ambivalence as a risk factor for prescription misuse, prescription
abuse and dependence symptoms, and alcohol use. Previous research has shown a
relationship between emotional ambivalence and other deleterious outcomes such as
poorer psychological health, poorer coping with pain, and increases in other negative
physical symptoms (King & Emmons, 1990). Therefore, ambivalence over emotional
expression likely plays an important role in both predicting problematic prescription use
and predicting poorer treatment outcomes for chronic pain. This study also provided
new evidence for the potential role of personality factors in identifying participants with
problematic prescription opioid use; however, inconsistent findings suggest a need for
further research in this area.
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Awareness of risk factors for prescription misuse can inform clinical practice by
those medical providers involved in the treatment of a patient with a chronic pain
condition. Specifically, early assessment of risk could help to identify patients who
should be more closely monitored and/or provided an intervention focused on
preventing problematic prescription use and use of alcohol and other drugs. Cost and
time limitations make it unlikely that intensive monitoring and intervention efforts could
be provided to all patients, thus honing in on the most risky personal characteristics is
imperative in providing these services. There is a clear need to continue to improve our
understanding of the risk factors that need to be monitored in patients receiving longterm opioid treatment for chronic pain, as well as improvement of clinical assessment
methods to gain accurate reports of problematic prescription use and use of alcohol and
other substances. There is also an evident need based on findings from the current
study to continue to focus efforts on understanding the role of personality factors and
emotional ambivalence in the development of problematic prescription opioid use in
chronic pain patients. Finally, there is also evidence that further development in
assessment methods, focused on understanding the role of meta-communication,
normalizing of problematic behaviors, and probing unclear responses, could lead to
better identification of patients already engaging in problematic prescription related
behaviors. Further understanding of role of these techniques, as well as dissemination
of these techniques to frontline treatment providers is suggested.
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Appendix A – Recruitment Brochure

Research Study: Chronic Pain,
Emotions, and Prescription Use

_______________________________

Evaluating Prescription and Drug Use Patterns
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Who is eligible?
We are seeking:
Adults who are attending the University Pain Clinic for management of a chronic pain disorder,
such as fibromyalgia, myofascial pain, irritable bowel syndrome, low back pain, chronic pelvic
pain, headaches, bladder pain, or other pain problems.
● We are looking for participants who have been taking opioid medications such as Vicodin,
Tylenol 3’s or 4’s, or other pain killers for at least 3 months.

●

How the study works
The study calls for a single session evaluation of your pain, physical health, and psychological
functioning. The evaluation can be completed at convenient locations on the Wayne State campus
or at the Detroit Medical Center.
Participation in the single session will take approximately 1 ½ hours of your time.
The evaluation will include questionnaires and possibly an interview. You will be asked about your
pain, health, stress, and your pattern of prescription use.

How do I participate?
You can find out more information about this study by contacting Lindsay Oberleitner at 313-5772773. She can provide you with more information about the study and set up a convenient time to
meet you at the Wayne State campus or at the Detroit Medical Center.

Compensation
We will pay you for your time. You will be paid $30 immediately after completing the study visit.
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Wayne State University

Investigator:
Mark A. Lumley, Ph.D.
Department of Psychology
Wayne State University
Todd Lininger, M.D.
University Pain Clinic

Research Personnel:
Lindsay Oberleitner
Kathryn Zumberg
Amy Loree

For more information about this study, please contact the
research team:
(313) 577-2773

Or visit our website:
http://clas.wayne.edu/healthlab/

and click on the Current Studies link
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Appendix B – Telephone Script
Telephone Script for Substance Abuse in Chronic Pain
Hello <insert patient’s name>, my name is _________ and I’m calling from Wayne State
University. I’m returning your call regarding interest in our chronic pain and medication use
study. You said you were interested in learning more about a study that we are doing of chronic
pain and medication use.
Do you mind if I ask you a few quick questions regarding your treatment? How long have you
been prescribed a pain medication? What medication are you currently prescribed?
(if they have been taking an opioid for 3mos continue with choice 1, if not follow to choice 2)
We hope that you are open to meeting, learning more about the study, and possibly
participating. May we set up your appointment now?
2. Thank you for your interest in our study. Unfortunately you do not meet the requirements
for our study as you need to have been taking an opioid pain medication for at least 3
months. If you are still interested in <insert time until they reach 3 months> please give
us a call and we would be happy to schedule a visit with you.
1.

Can I tell you briefly about this project? If you are interested, we can set up an appointment to
go over the details and the consent form.
This study is designed to evaluate medication use, alcohol and other substance use patterns in
chronic pain patients and how a variety of factors such as severity of pain, coping with pain,
ways of thinking, and ways of dealing with emotions.
If you participate, we would need to meet at the University Pain Clinic or the Simon’s Building
at Wayne State for about 1 ½ for an assessment of the various factors I just described to you.
Most of these are questionnaires that you will complete, but we may also do an interview.
We are going to pay you for your time. We will give you $30 right when you finish the session.
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Appendix C – Information Sheet
Research Information Sheet
Title of Study: Medication and Drug Use in Patients with Chronic Pain
Principal Investigator (PI):

Mark A. Lumley, Ph.D.
Department of Psychology
Wayne State University
313-577-2773

Purpose
You are being asked to be in a research study of factors related to medication and substance use
among people who have chronic pain. You are being asked to be in this study because you have
a chronic pain condition and have been prescribed a medication for your pain for at least 3
months. This study is being conducted at Wayne State University and will enroll approximately
120 participants. Please read this form and ask any questions you may have before agreeing
to be in the study.
In this research study, we are trying to understand patterns of prescription medication use in
patients who are being treated for chronic pain. The goals of this research are to learn:
a) how frequently prescription medication is misused and other substances (for example,
alcohol or marijuana) are used by people with chronic pain;
b) what characteristics of people are related to misusing medications or using substances;
c) how much people report when they complete questionnaires or are interviewed.
Study Procedures
If you agree to take part in this research study, you will be asked to complete a number of
questionnaires about your pain, functioning, mood, personality, and feelings. You will then be
asked either to talk with an interviewer or to complete questionnaires about possible traumatic
and experiences that you may have had, your use of alcohol and other substances, and your use
of your prescription medication. Which format (questionnaires or interview) you have will be
determined randomly (like by a flip of a coin); you have a 2 in 3 chance of being interviewed,
and a 1 in 3 chance of completing the questionnaires. Finally, you will be asked to demonstrate
how you might communicate different feelings to someone, such as being assertive, or telling
someone that you care. This communication exercise will be audiotaped. The entire session will
take about 1 ½ hours.
Benefits
As a participant in this research study, there may be no direct benefit for you; however,
information from this study may benefit other people now or in the future.
Risks
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By taking part in this study, you may experience the following risks: sharing personal
information about your prescription drug use, other substance use, and/or history of trauma may
be briefly upsetting or uncomfortable. In addition, you risk the loss of confidentiality under any
of the following conditions: If you are thought to be at risk for self-harm or harming another,
then this information may be released. If at any time during the study there is a concern that child
abuse or elder abuse has possibly occurred, then this information must be released to the
appropriate authorities. If at any time during the study there is a disclosure of illegal criminal
activities, illegal substance abuse, or violence, this information may be released to the
appropriate authorities. If at any time during the study it is discovered that you have a reportable
communicable disease (certain sexually transmitted diseases and/or HIV), then this information
must be released to the public health department. There may also be risks involved from taking
part in this study that are not known to researchers at this time.
Study Costs and Compensation
Participation in this study will be of no cost to you. For taking part in this research study, you
will be paid for your time and inconvenience. You will receive $30 for completing the single
session. Payment will be received in the form of cash immediately following completion of your
study session.
Confidentiality
You will be identified in the research records by a code name or number. There will be no list
that links your identity with this code.
Voluntary Participation /Withdrawal
Taking part in this study is voluntary. You are free to not answer any questions or withdraw at
any time. Your decision will not change any present or future relationships with Wayne State
University or its affiliates or other services you are entitled to receive.

Questions

If you have any questions about this study now or in the future, you may contact Mark Lumley,
Ph.D. or one of his research team members at the following phone number, (313) 577-2773. If
you have questions or concerns about your rights as a research participant, the Chair of the
Human Investigation Committee can be contacted at (313) 577-1628. If you are unable to contact
the research staff, or if you want to talk to someone other than the research staff, you may also
call (313) 577-1628 to ask questions or voice concerns or complaints.
Participation:
By completing the questionnaires, possible interview, and communication exercise you are
agreeing to participate in this study.
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Appendix D – Session Scripts

Script for Standard Interview
At the start of predictor portion
I am going to have you start by filling out some questionnaires about your family history, your
personality, and your typical way of dealing with emotions.(FLIP THROUGH THE PACKET) As
you can see, the scale will change as you go from scale to scale so please look carefully at the
instructions at the top of each page. If there are any items that you have questions about, please
feel free to ask me at any point or put a mark near it so that you can ask me about it later. Do
you have any questions?
At the start of randomized portion
First introduce the task:
Now I am going to go through a variety of questions about difficult experiences you may have
had, substance use and prescription use with you with you. We know that remembering when a
symptom started and how regularly it occurred can be difficult to remember, so please just try
your best to give the most accurate response you can.
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Meta-Communication Script for “Enhanced Group”
At the start of predictor portion
I am going to have you start by filling out some questionnaires about your family history, your
personality, and your typical way of dealing with emotions.(FLIP THROUGH THE PACKET) As
you can see, the scale will change as you go from scale to scale so please look carefully at the
instructions at the top of each page. If there are any items that you have questions about, please
feel free to ask me at any point or put a mark near it so that you can ask me about it later. Do
you have any questions?
General Approach Throughout Facilitated Portion:
• Focus on being “warm” toward the participant
• Make a conscious effort to not show shock or surprise at participant’s responses
• Have a good knowledge of substances, quantities, methods of use so that the participant
feels like you are knowledgeable and interested
• Use their first name and make sure they are comfortable and relaxed (make sure you
appear comfortable and relaxed also by body language and voice)
At the start of randomized portion
First introduce the task:
We are going to go through a variety of questions difficult experiences you may have had,
substance use and prescription use with you. We know that remembering when a symptom
started and how regularly it occurred can be difficult to remember, so please just try your best to
give the most accurate response you can.
Meta-communicate about comfort sharing
I know that many of these questions can be difficult to share and they might be questions that you
are not normally comfortable sharing with other people in your life.
It is normal to feel somewhat uncomfortable sharing information about really difficult
experiences in your life or about your use of alcohol, other substances, or about misusing your
prescription medication.
How are you feeling about sharing with me today?
What are your concerns about sharing with me today?
Discuss confidentiality in detail
Do you have any concerns about confidentiality that you would like to discuss?
I know that your prescription use and substance use might be an especially sensitive topic
because of concerns that other people, especially your doctor or the staff at the pain clinic might
find out about your response. I wanted to let you know again that I will not be sharing any of this
information with other people at the clinic or anyone else.
Normalize the experience of some of the symptoms
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I also want you to know that many people have experienced some of these symptom
Discuss the importance of honest answers
I also want you to know how important accurate answers are for this project. Your answers will
help us with determining who is most likely to be experiencing problems in the treatment of their
chronic pain. It may also help us to understand
At the beginning of the prescription drug portion
We are about to start the portion of the interview dealing with your use of your prescription pain
medication. I want you to know again that this information is confidential and also that many
people have used their prescriptions in ways other than how they are prescribed, and that many
people might also notice that they are having some problems or consequences from their use.
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There are currently few factors guiding physicians’ decisions as to whether an
individual patient may need additional regulation of pain medications because of risks.
The limited predictive factors applied to prescription opioid abuse in chronic pain
patients is surprising given the breadth of personal, cognitive, and emotional factors
explored in both chronic pain and substance abuse literatures broadly. The present
study had two purposes. First, concurrent risk factors for prescription misuse and
substance abuse in chronic pain patients were explored, specifically examining whether
the addition of emotional factors to the traditionally used risk factors improves prediction
of prescription and substance misuse. The present study also experimentally examined
whether an enhanced interview condition would lead to increased disclosure of
prescription misuse, other drug use, and traumatic events, by normalizing the
experience of substance use and trauma, and engaging in a conversation about
confidentiality of the information. Participants completed one session in which they were
assigned to report their prescription misuse, substance use, and trauma in one of the
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following formats: written/private, standard interview, enhanced interview. In the
enhanced condition, the interviewer followed an initial script addressing participants’
potential concerns about disclosure prior to questions regarding substance use and
trauma. In addition to replicating the role of personal and family history of substance use
problems, this study provided new evidence for the role of emotional ambivalence as a
risk factor for prescription misuse, prescription abuse and dependence symptoms, and
alcohol use. Interestingly, only younger age was predictive of cannabis use. This study
also provided evidence that further development in assessment methods, focused on
understanding the role of meta-communication, normalizing of problematic behaviors,
and probing unclear responses, could lead to better identification of patients already
engaging in problematic prescription related behaviors.
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